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The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among 
the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA-CVM), and U.S. 
Department of Agriculture (USDA).  The primary purpose of NARMS at CDC is to monitor antimicrobial resistance 
among foodborne enteric bacteria isolated from humans.  Other components of the interagency NARMS program 
include surveillance for resistance in enteric bacterial pathogens isolated from foods, conducted by the FDA 
Center for Veterinary Medicine 
(http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMoni
toringSystem/default.htm), and resistance in enteric pathogens isolated from animals, conducted by the USDA 
Agricultural Research Services (http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08).   
 
Many NARMS activities are conducted within the framework of CDC’s Emerging Infections Program (EIP), 
Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network 
(FoodNet).  In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also 
includes public health research into the mechanisms of resistance, education efforts to promote prudent use of 
antimicrobial agents, and studies of resistance in commensal organisms. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella and 
Escherichia coli O157 isolates in 14 sites. In 1997, testing of clinical Campylobacter isolates was initiated in the 
five sites participating in FoodNet. Testing of clinical Salmonella enterica serotype Typhi and Shigella isolates was 
added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, 
Salmonella ser. Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 
10 FoodNet states have been participating in Campylobacter surveillance. 
 
This annual report includes CDC’s surveillance data for 2006 for clinical non-Typhi Salmonella, Salmonella ser. 
Typhi, Shigella, Campylobacter and E. coli O157 isolates. Resistance trends and comparisons with previous 
years are included when appropriate. Antimicrobial subclasses defined by Clinical and Laboratory Standards 
Institute (CLSI) are used in data presentation and analysis. CLSI subclasses constitute major classifications of 
antimicrobial agents, e.g., aminoglycosides and cephalosporins. 
 
This report also includes World Health Organization’s categorization of antimicrobials of critical importance to 
human medicine (Table I) and data from the Escherichia coli Resistance Study, which is part of NARMS 
surveillance of commensal bacteria.  Appendix A summarizes the Escherichia coli Resistance Surveillance Pilot 
Study conducted in 2006.   
 


























In 2006, all 50 states participated in NARMS, representing approximately 298 million persons (Table II). 
Surveillance for antimicrobial resistance included non-Typhi Salmonella, Salmonella ser. Typhi, Shigella, and 
Escherichia coli O157. Campylobacter resistance to antimicrobial agents was monitored in 10 states that 
comprise the Foodborne Diseases Active Surveillance Network (FoodNet), representing approximately 44.5 
million persons (14.9% of the U.S. population). 
 
Clinically Important Antimicrobial Resistance Patterns 
 
In the United States, certain fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., 
ceftriaxone) are antimicrobial agents commonly used to treat severe Salmonella infections, including Salmonella 
ser. Typhi, the organism that causes typhoid fever. Fluoroquinolones are also used to treat Campylobacter 
infections. Nalidixic acid is an elementary quinolone; resistance to nalidixic acid correlates with decreased 
susceptibility or resistance to ciprofloxacin and possible treatment failure. Ceftiofur is a third-generation 
cephalosporin used in food animals in the United States; resistance to ceftiofur among Enterobacteriaceae 
correlates with decreased susceptibility to ceftriaxone. A substantial proportion of isolates tested by NARMS in 
2006 demonstrated resistance to these clinically important antimicrobial agents, as follows: 
• 19.6% (160/816) of Campylobacter isolates were resistant to the fluoroquinolone ciprofloxacin, compared with 
12.9% (28/217) in 1997 (OR=2.0, 95% CI [1.3, 3.1]). 
o 21.6% (21/97) of Campylobacter coli isolates were resistant to ciprofloxacin. 
o 19.5% (138/709) of Campylobacter jejuni isolates were resistant to ciprofloxacin. 
• 2.7% (60/2,184) of non-Typhi Salmonella isolates were resistant to the quinolone nalidixic acid, compared 
with 0.4% (5/1,324) in 1996 (OR=9.5, 95% CI [3.8, 23.8]). 
o Salmonella ser. Enteritidis was the most common serotype among nalidixic acid–resistant non-
Typhi Salmonella isolates: 48.3% (29/60) of quinolone–resistant isolates were serotype 
Enteritidis. 
o Nalidixic acid resistance in serotype Enteritidis was 7.0% (29/412) in 2006, compared with 0.9% 
(3/351) in 1996 (OR 95% CI [2.7–45.4]). 
• 3.6% (79/2,184) of non-Typhi Salmonella isolates were resistant to the third-generation cephalosporin 
ceftiofur, compared with 0.2% (2/1324) in 1996 (OR=29.8, 95% CI [7.3, 121.7]). 
o Salmonella ser. Newport was the most common serotype among ceftiofur–resistant non-Typhi 
Salmonella isolates: 34.1% (27/79) of ceftiofur–resistant isolates were serotype Newport. 
o Ceftiofur resistance among serotype Newport was 12.4% (27/217) in 2006, compared with 0% in 
1996. 
• 54.0% (175/324) of Salmonella ser. Typhi isolates were resistant to the quinolone nalidixic acid, compared 

























Multidrug resistance is described in NARMS by the number of antimicrobial subclasses and also by specific 
coresistant phenotypes. Antimicrobial subclasses are used as defined by CLSI (Table IV).  Multidrug resistance 
by the number of antimicrobial subclasses is defined as resistance to two or more CLSI subclasses. For non-
Typhi Salmonella, a common multidrug-resistant phenotype in 2006 includes resistance to at least ampicillin, 
chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline (ACSSuT). Another common 
phenotype includes resistance to at least ampicillin, chloramphenicol, streptomycin, 
sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-clavulanic acid, and ceftiofur, and decreased 
susceptibility to ceftriaxone (minimum inhibitory concentration ≥2 μg/mL) (MDR-AmpC). 
• 14.6% (319/2,184) of non-Typhi Salmonella isolates were resistant to two or more CLSI subclasses, and 
6.7% (146/2,184) were resistant to five or more CLSI subclasses. 
 
o Of the 319 non-Typhi Salmonella resistant to two or more CLSI subclasses, most were 
Salmonella ser. Typhimurium (34.2%, n=139), followed by serotype Newport (16.1%, n=35).  Of 
the 146 NTS resistant to five or more CLSI subclasses, most were serotype Typhimurium (21.9%, 
n=89), followed by serotype Newport (12.9%, n=28).  Serotypes Typhimurium and Newport were 
also the second and third most prevalent serotypes, respectively, among NTS submitted to 
NARMS in 2006. 
o 16.1% (35/217) of Salmonella ser. Newport isolates were resistant to two or more CLSI 
subclasses, and 12.9% (28/217) were resistant to five or more CLSI subclasses. 
o 34.2% (139/407) of Salmonella ser. Typhimurium isolates were resistant to two or more CLSI 
subclasses, and 21.9% (89/407) were resistant to five or more CLSI subclasses. 
o 2.9% (12/412) of Salmonella ser. Enteritidis isolates were resistant to two or more CLSI 
subclasses, and 0.2% (1/412) were resistant to five or more CLSI subclasses. 
 
• 5.5% (121/2,184) of non-Typhi Salmonella isolates had the ACSSuT resistance pattern, compared with 8.8% 
(116/1,324) in 1996 (Table 1.20). 
o 19.7% (80/407) of Salmonella ser. Typhimurium isolates were ACSSuT, compared with 33.7% 
(103/306) in 1996 (OR=0.5, 95% CI [0.3, 0.7]). 
o 12.0% (26/217) of Salmonella ser. Newport isolates were ACSSuT, compared with 5.9% (3/51) in 
1996. 
• 2.0% (43/2,184) of non-Typhi Salmonella isolates had the MDR-AmpC resistance pattern (Table 1.20). These 
isolates consisted of five different serotypes. In 1996, MDR-AmpC phenotype was not detected in any 
serotype. 
o 10.6% (23/217) of Salmonella ser. Newport isolates were resistant to the MDR-AmpC phenotype, 
compared with none (0/51) in 1996 (95% CI [1.4, infinity]). Although the prevalence of the MDR-
AmpC phenotype was higher than in 1996, prevalence of this phenotype among serotype 
Newport appears to be decreasing from the apparent peak of 25.0% in 2001. 




World Health Organization’s Categorization of Antimicrobials of Critical Importance to Human Medicine 
 
The World Health Organization (WHO) convened a panel of experts to develop a list of essential antimicrobial 
agents according to their importance to human medicine.  The participants categorized antimicrobial agents as 
either Critically Important, Highly Important, or Important based upon two criteria: (1) sole therapies or one of the 
few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be 
transmitted via non–human sources or diseases caused by organisms that may acquire resistance genes from 
non–human sources. 
 
• Antimicrobial agents are considered critically important if both criteria (1) and (2) are true. 
• Antimicrobial agents are highly important if either criteria (1) or (2) are true. 
• Antimicrobial agents are important if neither criterion are true. 
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β-Lactamase inhibitor combinations Amoxicillin-clavulanic acid 











Cephalosporin (1st generation) Cephalothin 
Cephamycins Cefoxitin 





II Highly important 
Tetracyclines Tetracycline 
 
III Important Lincosamides Clindamycin 
 
* Ceftiofur, a 3rd generation cephalosporin used in veterinary medicine, was included in NARMS testing since 1996. 










Table II:  Population size and number of isolates received and tested, NARMS, 2006  
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n (%) n (%) n (%) n (%) n (%)
Alabama 4,587,564 49 (2.2%) 2 (0.6%) 12 (3.0%) 2 (0.9%)
Alaska 676,301 4 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.4%)
Arizona 6,178,251 46 (2.1%) 4 (1.2%) 26 (6.5%) 1 (0.4%)
Arkansas 2,804,199 21 (1.0%) 1 (0.3%) 4 (1.0%) 6 (2.6%)
California‡ 26,240,388 214 (9.8%) 45 (13.9%) 2 (0.5%) 10 (4.3%) 34 (4.2%)
Colorado 4,751,474 34 (1.6%) 7 (2.2%) 8 (2.0%) 5 (2.1%) 90 (11.0%)
Connecticut 3,487,896 53 (2.4%) 4 (1.2%) 4 (1.0%) 2 (0.9%) 37 (4.5%)
Delaware 850,366 12 (0.5%) 0 (0.0%) 1 (0.2%) 1 (0.4%)
District of Columbia 585,419 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Florida 18,019,093 47 (2.2%) 15 (4.6%) 0 (0.0%) 0 (0.0%)
Georgia 9,318,715 102 (4.7%) 5 (1.5%) 55 (13.7%) 29 (12.4%) 144 (17.6%)
Hawaii 1,275,264 15 (0.7%) 5 (1.5%) 3 (0.7%) 1 (0.4%)
Houston, Texas§ 2,169,248 34 (1.6%) 9 (2.8%) 16 (4.0%) 1 (0.4%)
Idaho 1,461,183 9 (0.4%) 1 (0.3%) 0 (0.0%) 2 (0.9%)
Illinois 12,759,673 79 (3.6%) 12 (3.7%) 15 (3.7%) 8 (3.4%)
Indiana 6,294,124 45 (2.1%) 2 (0.6%) 2 (0.5%) 2 (0.9%)
Iowa 2,967,270 18 (0.8%) 0 (0.0%) 4 (1.0%) 3 (1.3%)
Kansas 2,756,267 13 (0.6%) 0 (0.0%) 5 (1.2%) 1 (0.4%)
Kentucky 4,199,440 30 (1.4%) 2 (0.6%) 9 (2.2%) 4 (1.7%)
Los Angeles¶ 9,880,908 63 (2.9%) 17 (5.2%) 6 (1.5%) 1 (0.4%)
Louisiana 4,243,634 43 (2.0%) 0 (0.0%) 5 (1.2%) 4 (1.7%)
Maine 1,313,355 9 (0.4%) 1 (0.3%) 1 (0.2%) 2 (0.9%)
Maryland 5,602,258 59 (2.7%) 12 (3.7%) 9 (2.2%) 2 (0.9%) 51 (6.3%)
Massachusetts 6,443,424 64 (2.9%) 3 (0.9%) 10 (2.5%) 3 (1.3%)
Michigan 10,083,878 47 (2.2%) 5 (1.5%) 4 (1.0%) 2 (0.9%)
Minnesota 5,143,134 40 (1.8%) 5 (1.5%) 11 (2.7%) 8 (3.4%) 156 (19.1%)
Mississippi 2,896,713 36 (1.6%) 2 (0.6%) 1 (0.2%) 1 (0.4%)
Missouri 5,832,977 55 (2.5%) 2 (0.6%) 24 (6.0%) 6 (2.6%)
Montana 945,428 4 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.4%)
Nebraska 1,759,779 14 (0.6%) 1 (0.3%) 7 (1.7%) 4 (1.7%)
Nevada 2,484,196 18 (0.8%) 1 (0.3%) 7 (1.7%) 6 (2.6%)
New Hampshire 1,308,824 10 (0.5%) 0 (0.0%) 1 (0.2%) 1 (0.4%)
New Jersey 8,640,218 56 (2.6%) 27 (8.3%) 16 (4.0%) 12 (5.2%)
New Mexico 1,937,916 13 (0.6%) 0 (0.0%) 9 (2.2%) 1 (0.4%) 41 (5.0%)
New York** 11,116,461 92 (4.2%) 13 (4.0%) 5 (1.2%) 34 (14.6%) 130 (15.9%)
New York City†† 8,250,567 77 (3.5%) 52 (16.0%) 13 (3.2%) 6 (2.6%)
North Carolina 8,845,343 82 (3.8%) 5 (1.5%) 3 (0.7%) 3 (1.3%)
North Dakota 636,453 3 (0.1%) 0 (0.0%) 11 (2.7%) 6 (2.6%)
Ohio 11,458,390 62 (2.8%) 9 (2.8%) 6 (1.5%) 7 (3.0%)
Oklahoma 3,568,132 29 (1.3%) 0 (0.0%) 7 (1.7%) 2 (0.9%)
Oregon 3,680,968 25 (1.1%) 3 (0.9%) 6 (1.5%) 3 (1.3%) 93 (11.4%)
Pennsylvania 12,388,055 92 (4.2%) 7 (2.2%) 2 (0.5%) 3 (1.3%)
Rhode Island 1,058,991 8 (0.4%) 2 (0.6%) 1 (0.2%) 1 (0.4%)
South Carolina 4,324,799 9 (0.4%) 1 (0.3%) 1 (0.2%) 0 (0.0%)
South Dakota 787,380 8 (0.4%) 1 (0.3%) 10 (2.5%) 3 (1.3%)
Tennessee 6,068,306 91 (4.2%) 1 (0.3%) 9 (2.2%) 1 (0.4%) 40 (4.9%)
Texas‡‡ 21,198,286 66 (3.0%) 12 (3.7%) 10 (2.5%) 1 (0.4%)
Utah 2,585,155 3 (0.1%) 2 (0.6%) 0 (0.0%) 0 (0.0%)
Vermont 620,196 5 (0.2%) 0 (0.0%) 1 (0.2%) 1 (0.4%)
Virginia 7,628,347 64 (2.9%) 20 (6.2%) 6 (1.5%) 6 (2.6%)
Washington 6,360,529 37 (1.7%) 2 (0.6%) 8 (2.0%) 7 (3.0%)
West Virginia 1,806,760 22 (1.0%) 0 (0.0%) 3 (0.7%) 5 (2.1%)
Wisconsin 5,568,505 46 (2.1%) 4 (1.2%) 11 (2.7%) 8 (3.4%)
Wyoming 512,573 7 (0.3%) 0 (0.0%) 10 (2.5%) 3 (1.3%)
Total 298,362,973 2184 (100.0%) 324 (100.0%) 402 (100.0%) 233 (100.0%) 816 (100.0%)
* US Census Bureau, 2006
† Campylobacter  isolates are submitted only from FoodNet sites; total population size of FoodNet sites was 44,531,182
‡ Excluding Los Angeles County
§ Houston City
¶ Los Angeles County
** Excluding New York City
†† Five burroughs of New York City (Bronx, Brooklyn, Manhattan, Queens, Staten Island)
‡‡







Table III: Summary of trend analysis of the proportion of specific resistance phenotypes among 
Campylobacter, non-Typhi Salmonella, and Salmonella ser. Typhi isolates, 2006 
Resistance Phenotype Reference Year Odds Ratio [95% CI]* 
Ciprofloxacin resistance in Campylobacter 1997 2.0 [1.3–3.1] 
Nalidixic acid resistance in non-Typhi 
Salmonella 1996 9.5 [3.8–23.8] 
Nalidixic acid resistance in Salmonella 
ser. Enteritidis 1996 –
† [2.7–45.4]† 
Ceftiofur resistance in non-Typhi 
Salmonella 1996 29.8 [7.3–121.7] 
Nalidixic acid resistance in Salmonella 
ser.Typhi 1999 5.2 [3.3–8.1] 
ACSSuT resistance in Salmonella ser. 
Typhimurium‡ 1996 0.5 [0.3–0.7] 




* For logistic regression models that adjusted for site, odds ratios (ORs) (2006 vs. reference year) and 95% confidence 
intervals (CIs) were calculated using unconditional maximum likelihood estimation. 
† Model included only year. In the analysis, the maximum likelihood estimate of the OR did not exist; only the 95% CIs, 
calculated using exact unconditional methods, are reported. 
‡ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline. 
§ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-




Surveillance and Laboratory Testing Methods  
 
 
Surveillance Sites and Isolate Submissions  
 
In 2006, NARMS conducted nationwide surveillance among approximately 298 million persons (2006 U.S. 
Census Bureau estimates). Public health laboratories systematically selected every 20th non-Typhi Salmonella 
(i.e., all Salmonella serotypes except serotype Typhi), Shigella, and Escherichia coli O157 isolate as well as every 
Salmonella ser. Typhi isolate received at their laboratories and forwarded these isolates to CDC for antimicrobial 
susceptibility testing. 
 
Starting in 2005, a new scheme for Campylobacter isolate submission was initiated.  Public health laboratories of 
the 10 state health departments that participated in CDC’s Foodborne Diseases Active Surveillance Network 
(FoodNet) forwarded a representative sample of Campylobacter isolates to CDC for susceptibility testing. The 
FoodNet sites, representing approximately 45 million persons (2006 U.S. Census Bureau estimates), included 
California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and 
Tennessee.  Depending on burden of Campylobacter in each FoodNet site, one of three methods was used to 
obtain a representative sample of Campylobacter isolates for submission to CDC:  all isolates received by 
Georgia, Maryland, New Mexico, Oregon, and Tennessee; every other isolate from California, Colorado, 
Connecticut, and New York; and every fifth isolate from Minnesota. From 1997 to 2004, one Campylobacter 
isolate was submitted each week from participating FoodNet sites to NARMS.  This submission scheme was 








Testing of Salmonella, Shigella, and Escherichia coli O157  
  
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre
®
, Trek 
Diagnostics, Westlake, OH) to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial 
agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole (Table IV). Before 2004, sulfamethoxazole was used instead of sulfisoxazole to represent the 
sulfonamides. Interpretive criteria defined by CLSI were used when available. The resistance breakpoint for 
amikacin, according to CLSI guidelines, is ≥64 μg/mL. In 2002 and 2003, a truncated broth microdilution series 
was used for amikacin testing (0.5-4 µg/mL).  For isolates that grew in all amikacin dilutions on the Sensititre
   
panel (MIC>4 μg/mL), ETest (AB BIODISK, Solna, Sweden) was performed to determine amikacin MIC. The 
amikacin ETest strip range of dilutions was 0.016-256 μg/mL. Since 2004, amikacin had a full range of dilutions 
(0.5-64 µg/mL) on the Sensititre panel (CMV1AGNF). 
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Table IV: Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia coli 
O157 isolates, NARMS, 2006 
Breakpoints 
CLSI Subclass Antimicrobial Agent 
Antimicrobial Agent 
Concentration 
Range (μg/mL) Susceptible Intermediate Resistant 
Amikacin 0.5–64 ≤16 32 ≥64 
Gentamicin 0.25–16 ≤4 8 ≥16 
Kanamycin 8–64 ≤16 32 ≥64 
Aminoglycosides 
Streptomycin* 32–64 ≤32  ≥64 
Aminopenicillins Ampicillin 1–32 ≤8 16 ≥32 
β-Lactamase inhibitor 
combinations Amoxicillin-clavulanic acid 1/0.5–32/16 ≤8 / ≤4 16/8 ≥32 / ≥16 
Cephalosporin 
(1st generation) Cephalothin
† 2–32 ≤8 16 ≥32 
Ceftiofur 0.12–8 ≤2 4 ≥8 Cephalosporins 
(3rd generation) Ceftriaxone 0.25–64 ≤8 16–32 ≥64 
Cephamycins Cefoxitin 0.5–32 ≤8 16 ≥32 
Folate pathway inhibitors Trimethoprim- sulfamethoxazole 0.12/2.4–4/76 ≤2 / ≤38  ≥4 / ≥76 
Phenicols Chloramphenicol 2–32 ≤8 16 ≥32 
Ciprofloxacin 0.015–4 ≤1 2 ≥4 
Quinolones 
Nalidixic acid 0.5–32 ≤16  ≥32 
Sulfamethoxazole 16–512 ≤256  ≥512 
Sulfonamides‡ 
Sulfisoxazole 16–256 ≤256  ≥512 
Tetracyclines Tetracycline 4–32 ≤4 8 ≥16 
* No CLSI breakpoints; resistance breakpoint used in NARMS is ≥64 µg/mL. 
† Cephalothin has not been tested since 2003, but was tested in earlier years for Salmonella, Shigella, and E. coli O157. 




Additional Testing of Salmonella Strains 
 
Cephalosporin Retesting of Isolates from 1996-1998 
 
Review of Salmonella isolates tested in NARMS during 1996 to 1998 gave conflicting cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC and, in some cases, did not exhibit an elevated MIC to other β-lactams. Because these findings 
suggested that some previously reported results were inaccurate, we retested, using the 2003 NARMS Sensititre® 
plate, isolates of Salmonella tested in NARMS during 1996 to 1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or 




Salmonella serotype reported by the submitting laboratory was accepted with few exceptions. Serotype was 
confirmed by CDC for isolates that underwent subsequent molecular analysis for publication.  Because of 
challenges associated with interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed 
for isolates reported as Salmonella ser. Paratyphi B by the submitting laboratory (serotype Paratyphi B is by 
definition unable to ferment L(+) tartrate). To distinguish Salmonella serotypes Paratyphi B and Paratyphi B var 
L(+) tartrate+ (formerly serotype Java), CDC performed Jordan’s tartrate test and/or Kauffmann’s tartrate test on 
all Salmonella ser. Paratyphi B isolates from 1996 to 2006 for which the tartrate result was not reported or was 
reported to be negative. Isolates negative for tartrate fermentation by both assays were categorized as serotype 
Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as serotype 
Paratyphi B var L(+) tartrate+. Confirmation of other biochemical reactions or somatic and flagellar antigens was 
not performed at CDC.  
 
Because of increased submissions of Salmonella ser. I 4,[5],12:i:- in 2006,, and recognition of the possibility that 
this serotype may have been under reported in previous years, isolates reported as serogroup B and tested in 
NARMS during 1996 to 2006 were reviewed for additional information; isolates that could be clearly identified as 
serogroup B, first-phase flagellar antigen “i”, second phase flagellar antigen absent were categorized in this report 






Testing of Campylobacter 
 
Changes in testing methods in 2005 
 
Starting in 2005, there were two major changes in the methodology used for Campylobacter.  First, a surveillance 
scheme for selecting a representative sample of Campylobacter isolates for submission by FoodNet sites was 
implemented in 2005, which changed from a previous scheme that selected one Campylobacter isolate each 
week for submission during 1997 to 2004. In 2005 and 2006, Campylobacter isolates were susceptibility tested 
using Sensititre (Trek Diagnostics, Westlake, OH); isolates had been tested by Etest (AB BIODISK, Solna, 
Sweden) from 1997 to 2004.  Second, florfenicol replaced chloramphenicol as the phenicol subclass 
representative drug, and telithromycin was added to the NARMS panel of agents tested in 2005. 
 
 
Identification/Speciation and Antimicrobial Susceptibility Testing 
 
In 2005 and 2006, isolates were confirmed as Campylobacter by determination of typical morphology 
using dark-field microscopy, and reactivity to catalase and oxidase tests. Identification of C. jejuni was 
performed using the hippurate hydrolysis test. Hippurate-positive isolates were identified as C. jejuni. 
Hippurate-negative isolates were further characterized with polymerase chain reaction (PCR) assay with 
specific targets for C. jejuni (mapA or hipO gene) or C. coli-specific ceuE gene (Linton et al 1997, 
Gonzales et al. 1997, Pruckler et al. 2006). The same methodology was used during 1997–2002.
   
In 2003 and 2004, putative Campylobacter isolates were identified as C. jejuni or C. coli using BAX® 
System PCR Assay according to the manufacturer's instructions (DuPont Qualicon, Wilmington, DE). 
Isolates not identified as C. jejuni or C. coli were further characterized by other PCR assays (Linton et al. 
1996) or sent to the CDC Campylobacter Reference Laboratory.  
Beginning in 2005, the broth microdilution methodology (Sensititre
®
,Trek Diagnostics, Westlake, OH) was used to 
determine the MICs for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, erythromycin, 
florfenicol, gentamicin, nalidixic acid, telithromycin, and tetracycline (Table V). Florfenicol replaced 
chloramphenicol in the NARMS panel to represent the phenicol antimicrobial subclass.  Similar to the 2004 report, 
CLSI interpretive criteria for erythromycin, ciprofloxacin, and tetracycline (published in 2006) and revised NARMS 
criteria for azithromycin were used for all years in this report. 
 
In annual reports published before 2004, these CLSI 
interpretive criteria were not available, and NARMS used resistance breakpoints for azithromycin and 
erythromycin that were lower than the new and revised breakpoints.
 
 In addition, revised NARMS interpretive 
criteria, adopted from the FDA-CVM arm of NARMS, have been used for clindamycin, gentamicin, and nalidixic 
acid since 2004.  From 1997 to 2004, Etest® (AB Biomerieux, Solna, Sweden)was used for susceptibility testing 





Table V: Antimicrobial agents used for susceptibility testing of Campylobacter isolates, NARMS, 1997–
2006 
Breakpoints 
CLSI Subclass Antimicrobial Agent 
Antimicrobial Agent 
Concentration Range (µg/mL)
Susceptible Intermediate Resistant 
Aminoglycosides Gentamicin 0.12–32 0.016–256* ≤2 4 ≥8 
Ketolides Telithromycin† 0.015–8 ≤4 8 ≥16 
Lincosamides Clindamycin 0.03–16 0.016–256* ≤2 4 ≥8 
Azithromycin 0.015–64 0.016–256* ≤2 4 ≥8 Macrolides 
Erythromycin 0.03–64 0.016–256* ≤8 16 ≥32 
Chloramphenicol‡ 0.016–256* ≤8 16 ≥32 
Phenicols 
Florfenicol§ 0.03–64 ≤4 N/A N/A 
Ciprofloxacin 0.015–64 0.002–32* ≤1 2 ≥4 Quinolones 
Nalidixic acid 4–64 0.016–256* ≤16 32 ≥64 
Tetracyclines Tetracycline 0.06–64 0.016–256* ≤4 8 ≥16 
 
* Etest dilution range used from 1997–2004. 
† Telithromycin added to NARMS panel in 2005. 
‡ Chloramphenicol, tested from 1997–2004, was replaced by florfenicol in 2005.  





Known mechanisms of quinolone resistance in Campylobacter are expected to confer equivalent susceptibilities 
to nalidixic acid and ciprofloxacin. Similarly, known mechanisms of macrolide resistance are expected to confer 
equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting 
results was performed by broth microdilution methods (Sensititre
®
, Trek Diagnostics, Westlake, OH). Totals 




For all pathogens, MICs were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was 
restricted to one isolate (per genus under surveillance) per patient based on the first isolate collected for non-
Typhi Salmonella, E.coli 0157, Shigella, and Campylobacter.  If two or more isolates were received for the same 
patient for Salmonella Typhi, the first blood isolate collected would be included in analysis.  If no blood isolates 
were submitted, the first isolate collected would be included in analysis.  Where established, CLSI interpretive 
criteria were used; streptomycin resistance was defined as MIC ≥64 μg/mL (Table IV). The 95% confidence 
intervals (CIs) for the percentage of resistant isolates are included in the MIC distribution tables. The 95% CIs 
were calculated using the Clopper-Pearson exact method.
 
Multidrug resistance by CLSI antimicrobial subclass 
was defined as resistance to two or more subclasses.  
When describing results for several years, multidrug resistance for Salmonella and E. coli O157 isolates was 
limited to the nine CLSI subclasses tested in all years from 1996 through 2005 represented by 13 agents: 
amoxicillin-clavulanic acid, ampicillin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, 
kanamycin, nalidixic acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole. For Salmonella ser. Typhi and Shigella, results for several years included the nine CLSI 
subclasses tested in all years from 1999 through 2006 represented by 14 agents (13 antimicrobial agents 
mentioned above and amikacin). Similarly, when describing multidrug resistance for several years for 





1997 through 2006, represented by ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, 
nalidixic acid, and tetracycline.  
Logistic regression was performed to assess the change in antimicrobial resistance among Salmonella and 
Campylobacter isolates tested in NARMS in 2006 compared with resistance in the reference years: 1996 for non-
Typhi Salmonella, 1999 for Salmonella ser. Typhi, and 1997 for Campylobacter.  The analysis included the 
following: 
1. Non-Typhi Salmonella: resistance to nalidixic acid, resistance to ceftiofur, resistance to one or more CLSI 
subclasses 
2. Salmonella ser. Typhimurium: resistance to at least ACSSuT 
3. Salmonella ser. Enteritidis: resistance to nalidixic acid 
4. Salmonella ser. Newport: resistance to at least MDR-AmpC 
5. Salmonella ser. Typhi: resistance to nalidixic acid 
6. Campylobacter species: resistance to ciprofloxacin 
7. C. jejuni: resistance to ciprofloxacin 
 
The final regression models for non-Typhi Salmonella, and final models for serotypes Typhimurium and Typhi, 
adjusted for site using the nine Public Health Service geographic regions described in the Public Health 
Laboratory Information System (PHLIS [http://www.cdc.gov/ncidod/dbmd/phlisdata/]) based on the patient’s state 
of residence. The PHLIS regions are East North Central, East South Central, Mid-Atlantic, Mountain, New 
England, Pacific, South Atlantic, West North Central, and West South Central. For all regression models that 
adjusted for site, odds ratios (ORs), and 95% confidence intervals (CIs) were calculated using unconditional 
maximum likelihood estimation. In the final regression models for serotypes Enteritidis and Newport, which 
included only year and used exact unconditional methods, the maximum likelihood estimate of the OR did not 
exist; only the 95% CIs are reported.  For Campylobacter, the final regression models adjusted for site using 
patient’s state of residence. The adequacy of model fit was assessed in several ways. The significance of the 
main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was also used to test for 
significance of interaction between site and year, although the power of the test to detect a single site-specific 
interaction was low. The Hosmer and Lemeshow goodness-of-fit test also was used. Finally, residual analysis 
was performed to examine the influence of individual observations. Having assessed that the main effect of year 








Results   
 
 
1. Non-Typhi Salmonella  
 
In non-Typhi Salmonella, an increase in resistance to two clinically important subclasses, (quinolones, 
represented by nalidixic acid and third-generation cephalosporins, represented by ceftiofur), was observed from 
1996 to 2006.  Nalidixic acid resistance increased from 0.4% to 2.7% and ceftiofur resistance increased from 
0.2% to 3.6%. Resistance to at least ACSSuT was one of the most common multidrug-resistance phenotypes in 
2006.  This phenotype was found among 5.5% of non-Typhi Salmonella isolates, lower in prevalence than in 2005 
(6.9%), and 1996 (8.8%).
 
 
In 2006, CDC received 2,276 non-Typhi Salmonella isolates, of which 2,184 (96.0%) were viable non-duplicates 
and tested for antimicrobial susceptibility (Table II). The antimicrobial agent with the highest prevalence of 
resistance was tetracycline (13.4%), followed by sulfisoxazole (12.0%), ampicillin (10.9%), and streptomycin 
(10.7%).  
 
Fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) are commonly used 
to treat severe Salmonella infections. Nalidixic acid is an elementary quinolone; resistance to nalidixic acid 
correlates with decreased susceptibility to ciprofloxacin and possible treatment failure. Ceftiofur is a third-
generation cephalosporin used in food animals in the United States; resistance to ceftiofur correlates with 
decreased susceptibility to ceftriaxone. In 2006, the prevalence of resistance among non-Typhi Salmonella 
isolates was 2.7% for quinolones (represented by nalidixic acid) and 3.6% for third-generation cephalosporins 
(represented by ceftiofur) (Table 1.02). 
 
 
The prevalence of nalidixic acid resistance increased from 0.4% (5/1,324) in 1996 to 2.7% (60/2,184) in 2006 
(Table 1.02), a statistically significant increase (OR=9.5, 95% CI [3.8, 23.8]). The prevalence of ceftiofur 
resistance increased from 0.2% (2/1,324) in 1996 to 3.6% (79/2,184) in 2006, a statistically significant increase 
(OR=29.8, 95% CI [7.3, 121.7]).   
 
Of the 2,184 non-Typhi Salmonella isolated in 2006, 1,752 (80.2%) showed no resistance to the drugs tested, 
similar to 2005 (80.6%) (Table 1.03). In 2006, 432 (19.8%) were resistant to one or more CLSI subclasses, 319 
(14.6%) to two or more subclasses, 258 (11.8%) to three or more subclasses, 183 (8.4%) to four or more 
subclasses, and 146 (6.7%) to five or more subclasses.  There was a statistically significant decline in resistance 
to one or more subclass from 33.8% in 1996 to 19.8% in 2006 (OR=0.6, 95% CI [0.5, 0.7]).  
 
In 2006, resistance to at least ACSSuT was one of the most common multidrug-resistance phenotypes.  This 
phenotype was found among 5.5% of non-Typhi Salmonella isolates, lower in prevalence than in 2005 (6.9%), 
and 1996 (8.8%).  Another common multidrug-resistant phenotype among non-Typhi Salmonella was resistance 
to at least MDR-AmpC, and 2.0% of the isolates displayed this pattern. The prevalence of the MDR-AmpC 
phenotype increased from 0% (0/1,324) in 1996 to 2.0% (43/2,184) in 2006.  Isolates that demonstrate the MDR-
AmpC phenotype also exhibit decreased susceptibility (≥2 µg/mL) to ceftriaxone.  Six (0.3%) isolates were 
resistant to both nalidixic acid and ceftiofur (Table 1.03); this pattern was first detected in 1997. 
 
In 2006, serotypes were identified for a higher proportion of isolates in NARMS (97.3%) than in the Public Health 
Laboratory Information System (PHLIS) (86.1%) (Table 1.04). The 20 most common serotypes accounted for 
81.8% of isolates in NARMS and 70.2% in PHLIS.  The same three most common serotypes were reported in 
NARMS and PHLIS, which accounted for 47.4% of isolates in NARMS and 41.9% in PHLIS. In NARMS; 2.2% of 
isolates were not completely serotyped in 2006, which was an increase compared with 1.0% in 2005. In 2006 
Salmonella ser. Enteritidis was the most commonly reported serotype, whereas Typhimurium was the most 
common serotype reported to NARMS in previous years.  Salmonella subspecies I 4,[5],12:i:- was the fourth most 
prevalent serotype reported to NARMS in 2006, whereas it was the 12th most common in 2005. It is not yet clear 
whether isolation rates or changes in reporting are responsible for these serotype prevalence changes. 
 















%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.3] 13.3 69.5 15.4 1.7 0.1 0.0
Gentamicin 0.3 2.1 [1.6–2.9] 70.4 25.7 1.3 0.0 0.0 0.3 1.1 1.0
Streptomycin NA 11.0 [9.6–12.4] 89.0 5.9 5.0
Aminopenicillins Ampicillin 0.0 11.3 [10.0–12.8] 76.0 11.9 0.6 0.2 0.1 11.2
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 5.1 3.2 [2.5–4.0] 85.2 2.9 0.8 2.8 5.1 1.0 2.1
Ceftiofur 0.2 2.9 [2.2–3.7] 0.5 0.9 58.2 36.5 0.7 0.2 0.1 2.8
Ceftriaxone 2.5 0.1 [0.0–0.4] 97.0 0.1 0.0 0.2 1.3 1.2 0.0 0.1
Ciprofloxacin 0.0 0.0 [0.0–0.3] 96.2 1.0 0.3 1.1 0.6 0.8 0.0 0.0
Nalidixic acid NA 2.4 [1.8–3.2] 0.1 0.5 31.5 63.8 1.2 0.4 2.4
Aminoglycosides Kanamycin 0.1 3.4 [2.7–4.3] 96.4 0.0 0.1 0.2 3.2
Cephamycins Cefoxitin 0.0 3.0 [2.3–3.9] 0.4 35.9 47.2 12.3 1.1 0.0 0.7 2.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.7 [1.2–2.3] 91.2 6.7 0.3 0.0 1.7
Phenicols Chloramphenicol 0.5 7.7 [6.6–9.0] 2.0 64.6 25.1 0.5 0.1 7.6
Sulfonamides Sulfisoxazole NA 12.5 [11.1–14.0] 23.4 48.7 14.6 0.7 0.1 12.5
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Figure 1.02: Proportional chart, a categorical graph of a squashtogram 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.9] 2.9 74.4 20.9 1.7
Gentamicin 0.2 2.7 [1.4–4.8] 60.0 34.6 2.5 0.2 1.0 1.7
Streptomycin NA 29.5 [25.1–34.2] 70.5 17.2 12.3
Aminopenicillins Ampicillin 0.0 28.3 [23.9–32.9] 61.4 10.1 0.2 28.3
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 14.5 4.4 [2.6–6.9] 69.8 2.0 0.7 8.6 14.5 0.2 4.2
Ceftiofur 0.0 4.2 [2.5–6.6] 0.5 48.9 45.7 0.7 4.2
Ceftriaxone 2.2 0.2 [0.0–1.4] 95.8 1.7 1.0 1.2 0.2
Ciprofloxacin 0.0 0.2 [0.0–1.4] 96.3 2.0 0.2 0.2 1.0 0.2
Nalidixic acid NA 0.7 [0.2–2.1] 0.2 48.4 49.1 0.7 0.7 0.7
Aminoglycosides Kanamycin 0.0 5.2 [3.2–7.8] 94.6 0.2 5.2
Cephamycins Cefoxitin 0.2 3.9 [2.3–6.3] 26.8 60.4 7.4 1.2 0.2 2.2 1.7
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 2.2 [1.0–4.2] 75.9 21.4 0.2 0.2 2.2
Phenicols Chloramphenicol 0.7 22.1 [18.2–26.5] 2.5 49.9 24.8 0.7 22.1
Sulfonamides Sulfisoxazole NA 33.4 [28.8–38.2] 11.3 51.6 3.7 33.4
Tetracyclines Tetracycline 0.0 31.7 [27.2–36.5] 68.3 3.9 13.0 14.7
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides




























Table 1.01: Minimum inhibitory concentrations (MICs) and resistance of non-Typhi Salmonella isolates to 
antimicrobial agents, 2006 (N=2,184) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.2] 9.9 69.8 18.5 1.7 0.1 0.0
Gentamicin 0.5 2.0 [1.5–2.7] 64.6 31.7 1.1 0.2 0.0 0.5 0.7 1.3
Streptomycin NA 10.7 [9.4–12.0] 89.3 5.3 5.4
Aminopenicillins Ampicillin 0.0 10.9 [9.6–12.3] 79.6 8.9 0.5 10.9
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 3.5 3.7 [3.0–4.6] 86.5 2.5 0.6 3.2 3.5 1.4 2.3
Ceftiofur 0.0 3.6 [2.9–4.5] 0.2 0.7 49.7 45.0 0.8 0.0 3.6
Ceftriaxone 2.8 0.2 [0.0–0.5] 96.3 0.0 0.1 0.5 1.5 1.4 0.1 0.1
Ciprofloxacin 0.0 0.1 [0.0–0.3] 94.2 2.5 0.2 1.4 0.7 0.8 0.0 0.1
Nalidixic acid NA 2.7 [2.1–3.5] 0.4 40.7 55.0 0.8 0.3 0.1 2.7
Aminoglycosides Kanamycin 0.2 2.9 [2.2–3.7] 96.7 0.2 0.2 0.0 2.8
Cephamycins Cefoxitin 0.3 3.5 [2.8–4.4] 0.3 28.5 55.4 11.0 0.9 0.3 1.5 2.0
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.6 [1.2–2.3] 88.4 9.5 0.4 0.1 1.6
Phenicols Chloramphenicol 0.7 6.4 [5.4–7.5] 1.9 61.0 29.9 0.7 6.4
Sulfonamides Sulfisoxazole NA 12.0 [10.7–13.5] 14.6 51.6 20.7 1.1 0.0 12.0
Tetracyclines Tetracycline 0.1 13.4 [12.0–14.9] 86.5 0.1 1.0 3.9 8.6
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides































Table 1.02: Percentage and number of non-Typhi Salmonella isolates resistant to antimicrobial agents, 
1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 1 0 0 0 0 0 1 0
Gentamicin 4.8% 2.9% 2.8% 2.1% 2.7% 1.9% 1.3% 1.4% 1.3% 2.1% 2.0%
(MIC ≥ 16) 63 38 41 32 37 27 27 26 24 44 44
Streptomycin 20.6% 21.4% 18.6% 16.7% 16.3% 17.0% 13.2% 15.0% 11.8% 11.0% 10.7%
(MIC ≥ 64) 273 278 272 250 224 241 265 279 212 225 233
Ampicillin 20.7% 18.3% 16.5% 15.5% 15.9% 17.4% 12.9% 13.6% 12.0% 11.3% 10.9%
(MIC ≥ 32) 274 238 241 232 219 247 259 254 216 232 238
Amoxicillin-clavulanic acid 1.1% 1.0% 1.7% 2.3% 3.9% 4.7% 5.3% 4.6% 3.7% 3.2% 3.7%
(MIC ≥ 32) 15 13 25 34 54 66 106 86 67 65 81
Ceftiofur 0.2% 0.5% 0.8% 2.0% 3.2% 4.1% 4.3% 4.5% 3.4% 2.9% 3.6%
(MIC ≥ 8) 2 6 12 30 44 58 87 83 61 60 79
Ceftriaxone 0.0% 0.1% 0.0% 0.3% 0.0% 0.0% 0.2% 0.4% 0.6% 0.1% 0.2%
(MIC ≥ 64) 0 1 0 5 0 0 4 8 10 3 4
Ciprofloxacin 0.0% 0.0% 0.1% 0.1% 0.4% 0.2% 0.0% 0.2% 0.2% 0.0% 0.1%
(MIC ≥ 4) 0 0 1 1 5 3 1 3 4 1 2
Nalidixic acid 0.4% 0.9% 1.4% 0.9% 2.5% 2.6% 1.8% 2.3% 2.6% 2.4% 2.7%
(MIC ≥ 32) 5 12 20 14 34 37 36 42 47 50 60
Aminoglycosides Kanamycin 5.0% 5.1% 5.7% 4.3% 5.6% 4.8% 3.8% 3.4% 2.8% 3.4% 2.9%
(MIC ≥ 64) 66 67 83 65 77 68 76 64 50 70 63
Cephalothin 2.9% 2.2% 2.3% 3.5% 4.0% 4.0% 5.0% 5.4% Not Not Not
(MIC ≥ 32) 39 29 33 53 55 57 101 100 Tested Tested Tested
Cefoxitin Not Not Not Not 3.2% 3.4% 4.3% 4.2% 3.5% 3.0% 3.5%
(MIC ≥ 32) Tested Tested Tested Tested 44 48 86 79 62 62 77
Trimethoprim-sulfamethoxazole 3.9% 1.8% 2.3% 2.0% 2.1% 2.0% 1.4% 1.9% 1.8% 1.7% 1.6%
(MIC ≥ 4) 51 24 34 30 29 28 28 36 32 34 36
Chloramphenicol 10.6% 10.1% 9.9% 9.2% 10.1% 11.6% 8.6% 10.0% 7.6% 7.7% 6.4%
(MIC ≥ 32) 140 131 145 137 139 164 172 187 136 159 139
Sulfamethoxazole/Sulfisoxazole† 20.3% 22.8% 19.4% 18.0% 17.1% 17.7% 12.8% 15.0% 13.2% 12.5% 12.0%
(MIC ≥ 512) 269 297 283 269 235 251 258 280 237 256 263
Tetracycline 24.2% 21.7% 20.2% 19.3% 18.6% 19.7% 14.9% 16.3% 13.5% 13.7% 13.4%
(MIC ≥ 16) 320 282 295 289 256 280 299 303 242 282 293
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 
















Table 1.03: Resistance patterns of non-Typhi Salmonella isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 1324 1301 1460 1495 1377 1419 2008 1864 1794 2052 2184
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 66.2% 68.4% 72.9% 74.2% 74.4% 72.3% 79.0% 77.7% 79.6% 80.6% 80.2%
 876 890 1064 1109 1024 1026 1586 1449 1428 1654 1752
Resistance ≥ 1 CLSI subclass* 33.8% 31.6% 27.1% 25.8% 25.6% 27.7% 21.0% 22.3% 20.4% 19.4% 19.8%
 448 411 396 386 353 393 422 415 366 398 432
Resistance ≥ 2 CLSI subclasses* 27.0% 24.1% 22.6% 20.4% 20.2% 22.1% 15.8% 17.7% 15.0% 14.8% 14.6%
 358 314 330 305 278 314 318 330 269 304 319
Resistance ≥ 3 CLSI subclasses* 18.1% 17.7% 16.7% 15.1% 15.6% 16.8% 12.2% 14.3% 11.7% 12.0% 11.8%
 240 230 244 225 215 239 244 266 210 247 258
Resistance ≥ 4 CLSI subclasses* 13.7% 13.7% 13.1% 12.2% 12.9% 14.2% 9.9% 11.6% 9.4% 9.1% 8.4%
 181 178 191 183 178 202 199 216 168 186 183
Resistance ≥ 5 CLSI subclasses* 10.0% 9.9% 10.1% 8.6% 9.9% 10.5% 8.3% 9.9% 8.1% 7.6% 6.7%
 132 129 147 129 137 149 167 185 146 156 146
At least ACSSuT† 8.8% 9.5% 8.9% 8.4% 8.9% 10.0% 7.8% 9.3% 7.1% 6.9% 5.5%
 116 124 130 125 122 142 156 173 128 141 121
At least ACSuTm‡ 0.8% 0.4% 0.9% 0.9% 1.0% 0.5% 1.0% 1.2% 0.6% 0.9% 0.7%
 10 5 13 14 14 7 21 23 10 18 15
At least ACSSuTAuCf§ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3% 2.0% 2.0%
 0 4 5 23 36 36 67 60 42 41 43
At least MDR-AmpC¶ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3% 2.0% 2.0%
 0 4 5 23 36 36 67 60 42 41 43
Resistance to quinolone** and cephalosporin†† 0.0% 0.2% 0.1% 0.1% 0.3% 0.3% 0.2% 0.2% 0.4% 0.3% 0.3%
 0 2 1 1 4 4 5 4 7 7 6
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)




Table 1.04: Twenty most common non-Typhi Salmonella serotypes in NARMS and the Public Health 
Laboratory Information System, 2006 
Rank Serotype n (%) Rank Serotype n (%)
1 Enteritidis 412 (18.9%) 1 Typhimurium 6872 (17.0%)
2 Typhimurium 407 (18.6%) 2 Enteritidis 6740 (16.6%)
3 Newport 217 (9.9%) 3 Newport 3373 (8.3%)
4 I 4,[5],12:i:- 105 (4.8%) 4 Heidelberg 1495 (3.7%)
5 Heidelberg 102 (4.7%) 5 Javiana 1433 (3.5%)
6 Javiana 80 (3.7%) 6 I 4,[5],12:i:- 1200 (3.0%)
7 Montevideo 62 (2.8%) 7 Montevideo 1061 (2.6%)
8 Paratyphi B var. L(+) tartrate+ 49 (2.2%) 8 Muenchen 753 (1.9%)
9 Oranienburg 48 (2.2%) 9 Oranienburg 719 (1.8%)
10 Muenchen 45 (2.1%) 10 Mississippi 604 (1.5%)
11 Agona 42 (1.9%) 11 Saintpaul 588 (1.5%)
12 Saintpaul 30 (1.4%) 12 Braenderup 561 (1.4%)
13 Braenderup 29 (1.3%) 13 Agona 538 (1.3%)
14 Thompson 26 (1.2%) 14 Infantis 491 (1.2%)
15 Stanley 25 (1.1%) 15 Thompson 447 (1.1%)
16 Mississippi 24 (1.1%) 16 Paratyphi B var. L(+) tartrate+ 417 (1.0%)
17 Infantis 22 (1.0%) 17 Stanley 315 (0.8%)
18 Hadar 22 (1.0%) 18 Tennessee 312 (0.8%)
19 Tennessee 21 (1.0%) 19 Hadar 275 (0.8%)
20 Berta 19 (0.9%) 20 Bareilly 256 (0.7%)
Subtotal 1787 (81.8%) Subtotal 28450 (70.2%)
All other serotypes 339 (15.5%) All other serotypes 6459 (15.9%)
Unknown serotype 6 (0.3%) Unknown serotype 4042 (10.0%)
Partially serotyped 49 (2.2%) Partially serotyped 1448 (3.6%)
Rough/Nonmotile isolates 3 (0.1%) Rough/Nonmotile isolates 110 (0.3%)
Subtotal 397 (18.2%) Subtotal 12059 (29.8%)








A. Salmonella ser. Enteritidis 
 
In 2006, Salmonella ser. Enteritidis was the most common non-Typhi Salmonella serotype in NARMS.  Most 
serotype Enteritidis isolates had no detected resistance.  However, nalidixic acid resistance increased from 0.9% 
in 1996 to 7.0% in 2006 (95% CI [2.7, 45.4]) (Table 1.06). 
 
In 2006, Salmonella ser. Enteritidis was the most common non-Typhi Salmonella serotype identified in NARMS, 
accounting for 18.9% (412/2,184) of non-Typhi Salmonella isolates (Table 1.04). Resistance was rare among 
serotype Enteritidis isolates tested in 2006. Most (88.6%) of the serotype Enteritidis isolates tested in 2006 had no 
detected resistance (Table 1.07).  However, there was a statistically significant increase in nalidixic acid 
resistance from 0.9% in 1996 to 7.0% in 2006 (95% CI [2.7, 45.4]) (Table 1.06).  Serotype Enteritidis was the 
most prevalent (48.3%) non-Typhi Salmonella serotype that had resistance to nalidixic acid (Table 1.20). 
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Table 1.05: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis 
isolates to antimicrobial agents, 2006 (N=412) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.9] 25.5 63.8 9.5 1.2
Gentamicin 0.0 0.2 [0.0–1.3] 82.5 16.7 0.5 0.2
Streptomycin NA 1.2 [0.4–2.8] 98.8 0.2 1.0
Aminopenicillins Ampicillin 0.0 4.4 [2.6–6.8] 84.5 11.2 4.4
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.5 0.5 [0.1–1.7] 93.4 2.2 1.2 2.2 0.5 0.2 0.2
Ceftiofur 0.0 0.5 [0.1–1.7] 0.2 0.5 30.1 68.4 0.2 0.5
Ceftriaxone 0.0 0.0 [0.0–0.9] 99.5 0.5
Ciprofloxacin 0.0 0.0 [0.0–0.9] 86.7 6.1 0.2 5.6 1.2 0.2
Nalidixic acid NA 7.0 [4.8–10.0] 18.9 73.1 0.7 0.2 7.0
Aminoglycosides Kanamycin 0.0 0.2 [0.0–1.3] 99.8 0.2
Cephamycins Cefoxitin 0.0 0.5 [0.1–1.7] 0.5 25.5 69.9 3.4 0.2 0.5
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.5 [0.1–1.7] 90.3 8.7 0.5 0.5
Phenicols Chloramphenicol 0.0 0.0 [0.0–0.9] 1.5 71.1 27.4
Sulfonamides Sulfisoxazole NA 1.5 [0.5–3.1] 11.4 63.3 23.3 0.5 1.5
Tetracyclines Tetracycline 0.2 1.7 [0.7–3.5] 98.1 0.2 0.2 1.5
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
II
Rank*
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
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Table 1.06: Percentage and number of Salmonella ser. Enteritidis isolates resistant to antimicrobial 
agents, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0 0
Gentamicin 4.8% 0.3% 0.4% 0.0% 0.3% 0.0% 0.3% 0.4% 0.4% 0.8% 0.2%
(MIC ≥ 16) 17 1 1 0 1 0 1 1 1 3 1
Streptomycin 2.0% 4.3% 1.6% 2.2% 0.0% 1.4% 1.8% 1.2% 2.2% 1.0% 1.2%
(MIC ≥ 64) 7 13 4 6 0 4 6 3 6 4 5
Ampicillin 20.5% 11.3% 6.1% 10.8% 7.5% 8.7% 7.1% 2.3% 4.1% 2.9% 4.4%
(MIC ≥ 32) 72 34 15 29 24 24 24 6 11 11 18
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.4% 0.0% 1.4% 0.6% 0.0% 0.0% 0.8% 0.5%
(MIC ≥ 32) 2 0 0 1 0 4 2 0 0 3 2
Ceftiofur 0.0% 0.3% 0.0% 0.4% 0.0% 2.2% 0.0% 0.0% 0.0% 0.5% 0.5%
(MIC ≥ 8) 0 1 0 1 0 6 0 0 0 2 2
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.9% 1.7% 2.0% 2.2% 2.2% 4.3% 3.9% 4.7% 6.6% 4.7% 7.0%
(MIC ≥ 32) 3 5 5 6 7 12 13 12 18 18 29
Aminoglycosides Kanamycin 0.0% 0.7% 0.4% 0.4% 0.3% 0.7% 0.3% 0.0% 0.7% 0.3% 0.2%
(MIC ≥ 64) 0 2 1 1 1 2 1 0 2 1 1
Cephalothin 4.0% 1.3% 0.0% 1.9% 0.9% 1.1% 0.6% 1.2% Not Not Not
(MIC ≥ 32) 14 4 0 5 3 3 2 3 Tested Tested Tested
Cefoxitin Not Not Not Not 0.0% 0.4% 0.0% 0.0% 0.0% 1.0% 0.5%
(MIC ≥ 32) Tested Tested Tested Tested 0 1 0 0 0 4 2
Trimethoprim-sulfamethoxazole 6.6% 1.3% 0.8% 0.7% 0.0% 0.7% 0.6% 0.8% 0.0% 0.5% 0.5%
(MIC ≥ 4) 23 4 2 2 0 2 2 2 0 2 2
Chloramphenicol 0.0% 0.7% 0.0% 0.4% 0.0% 0.0% 0.6% 0.4% 0.4% 0.5% 0.0%
(MIC ≥ 32) 0 2 0 1 0 0 2 1 1 2 0
Sulfamethoxazole/Sulfisoxazole† 8.5% 9.0% 2.0% 3.0% 0.9% 2.2% 1.8% 1.2% 1.8% 1.6% 1.5%
(MIC ≥ 512) 30 27 5 8 3 6 6 3 5 6 6
Tetracycline 16.8% 9.6% 6.6% 8.2% 1.9% 1.8% 4.5% 1.6% 3.3% 2.3% 1.7%
(MIC ≥ 16) 59 29 16 22 6 5 15 4 9 9 7
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 

















Table 1.07: Resistance patterns of Salmonella ser. Enteritidis isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 351 301 244 269 319 277 337 257 271 384 412
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 73.5% 77.4% 87.7% 83.6% 89.0% 86.6% 87.2% 91.8% 87.1% 91.9% 88.6%
 258 233 214 225 284 240 294 236 236 353 365
Resistance ≥ 1 CLSI subclass* 26.5% 22.6% 12.3% 16.4% 11.0% 13.4% 12.8% 8.2% 12.9% 8.1% 11.4%
 93 68 30 44 35 37 43 21 35 31 47
Resistance ≥ 2 CLSI subclasses* 19.1% 9.6% 6.6% 8.6% 1.9% 4.7% 4.2% 2.3% 3.0% 3.6% 2.9%
 67 29 16 23 6 13 14 6 8 14 12
Resistance ≥ 3 CLSI subclasses* 8.0% 3.0% 0.8% 1.1% 0.3% 2.9% 2.4% 0.8% 1.1% 2.1% 2.2%
 28 9 2 3 1 8 8 2 3 8 9
Resistance ≥ 4 CLSI subclasses* 4.6% 1.3% 0.0% 0.7% 0.0% 1.8% 1.5% 0.4% 0.7% 0.8% 0.7%
 16 4 0 2 0 5 5 1 2 3 3
Resistance ≥ 5 CLSI subclasses* 1.7% 0.7% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.7% 0.5% 0.2%
 6 2 0 1 0 0 1 1 2 2 1
At least ACSSuT† 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.4% 0.5% 0.0%
 0 1 0 1 0 0 1 1 1 2 0
At least ACSuTm‡ 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0%
 0 1 0 1 0 0 0 1 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0%
 0 0 0 1 0 0 0 0 0 1 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0%
 0 0 0 1 0 0 0 0 0 1 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.3% 0.0% 0.0% 0.3% 0.0% 0.0% 0.4% 0.0% 0.3% 0.0%
 0 1 0 0 1 0 0 1 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)






Resistance to nalidixic acid and decreased susceptibility to ciprofloxacin in 
Salmonella ser. Enteritidis, NARMS, 1996–2006 
 
 
Salmonella ser. Enteritidis is a leading cause of salmonellosis in the United States.  Serotype Enteritidis was the 
most common serotype reported to the National Antimicrobial Resistance Monitoring System (NARMS) and the 
second most common serotype among culture-confirmed infections reported to National Salmonella Surveillance 
System at CDC in 2006 (http://www.cdc.gov/ncidod/dbmd/phlisdata/default.htm).   Consumption of egg-containing 
products and chicken prepared outside the home are risk factors of human Salmonella ser. Enteritidis infections 
(Altekruse et al. 2006; Voetsch et al. 2009).  
 
While most non-Typhi Salmonella infections are self-limiting, antimicrobial agents, such as fluoroquinolones (e.g. 
ciprofloxacin) are essential to treat invasive infections (Mandell et al. 2000). Resistance to nalidixic acid (MIC ≥ 32 
μg/mL), a quinolone, correlates with decreased susceptibility to ciprofloxacin (MIC ≥ 0.125 μg/mL). 
Enterobacteriaceae, including Salmonella spp., most commonly develop resistance to quinolones by acquiring 
chromosomal point mutations in the genes encoding DNA gyrase (gyrA, gyrB) and DNA topoisomerase IV (parC,  
parE).  These mutations prevent quinolone drugs from binding to their targets, thereby enabling the bacteria to 
replicate (Crump et al. 2003).  While a single point mutation is sufficient to confer nalidixic acid resistance, two or 
more point mutations are required to confer ciprofloxacin resistance according to current CLSI definitions. (Jacoby 
2005). Additional plasmid-mediated mechanisms for decreased fluoroquinolone susceptibility include 
topoisomerase protection by Qnr proteins, acetylation by the Aac (6’)-lb-cr enzyme, and efflux by the QepA pump.  
Here we describe the trend in resistance to nalidixic acid and decreased susceptibility to ciprofloxacin among 
Salmonella ser. Enteritidis isolates in NARMS from 1996 to 2006.  Isolate submission and testing are described in 
the methods section of this report. 
Among Salmonella ser. Enteritidis submitted to NARMS, quinolone resistance was observed in 128 (3.7%) of 
3,422 isolates from 1996 to 2006. This annual report highlights that the proportion of nalidixic acid resistance 
among Salmonella ser. Enteritidis significantly increased from 3/351 (0.9%) in 1996 to 29/412 (7.0%) in 2006 
(95% CI [2.7, 45.4]).  While none of the isolates showed resistance to both nalidixic acid and ciprofloxacin, 
decreased susceptibility to ciprofloxacin also increased from 1996–2006.  As expected, nalidixic acid resistance 
was associated with decreased susceptibility to ciprofloxacin:  115 (90.0%) of 128 nalidixic acid–resistant isolates 
exhibited decreased susceptibility to ciprofloxacin, compared with 6 (0.2%) of 3,294 isolates that were not 
resistant to nalidixic acid (Chi-square, p <0.001) (Figure A).  Six isolates that showed decreased susceptibility to 
ciprofloxacin remained susceptible to nalidixic acid.  This phenotype could be due to the acquisition of plasmid-
mediated fluoroquinolone resistance mechanisms such as qnr, aac (6’)-lb-cr, or qepA.   Foodborne Salmonella 
ser. Enteritidis remains an important source for human salmonellosis infections in the United States. Continued 
public health surveillance for quinolone resistance and decreased susceptibility to fluoroquinolones, as well as 
identifying the mechanisms of resistance is critical and subsequent studies will be important in documenting these 
and other emerging mechanisms of resistance. 
 
 
Figure A: Percentage of Salmonella  ser. Enteritidis with nalidixic acid  
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B. Salmonella ser. Typhimurium 
 
In 2006, Salmonella ser. Typhimurium was the second most common non-Typhi Salmonella serotype in NARMS.  
The ACSSuT resistant phenotype in serotype Typhimurium decreased from 33.7% in 1996 to 19.7% in 2006.  
 
In 2006, Salmonella ser. Typhimurium was the second most common non-Typhi Salmonella serotype in NARMS, 
accounting for 18.6% (407/2,184) of non-Typhi Salmonella isolates (Table 1.04). Of the 407 serotype 
Typhimurium isolates tested, resistance was highest to sulfisoxazole (33.4%), tetracycline (31.7%), streptomycin 
(29.5%), ampicillin (28.3%), and chloramphenicol (22.1%) (Table 1.09). The prevalence of resistance among 
clinically important antimicrobial subclasses was 0.7% for quinolones (represented by nalidixic acid) and 4.2% for 
third-generation cephalosporins (represented by ceftiofur). 
 
Resistance to other antimicrobial agents decreased since 1996 (Table 1.09). Resistance to tetracycline 
decreased from 49.3% in 1996 to 31.7% in 2006; ampicillin, from 50.0% to 28.3%; streptomycin, from 51.6% to 
29.5%; chloramphenicol, from 39.9% to 22.1%; and gentamicin, from 4.2% to 2.7%. 
 
Of the 407 Salmonella ser. Typhimurium isolates tested in 2006, 62.4% (254/407) had no detected resistance, a 
decrease from the 65.2% (285/437) of isolates in 2005 (Table 1.10). In 2006, 34.2% (139/407) were resistant to 
two or more CLSI subclasses, compared with 33.2% (145/437) in 2005. Similarly, in 2006, 21.9% (89/407) were 
resistant to at least five subclasses, compared with 23.6% (103/437) in 2005. 
 
In 2006, the most common multidrug-resistant phenotype among Salmonella ser. Typhimurium was ACSSuT 
(19.7% of isolates). Since 1996, the prevalence of ACSSuT among Salmonella ser. Typhimurium decreased from 
33.7% to 19.7%. In the logistic regression model, this decrease was statistically significant (OR=0.5, 95% CI [0.3, 
0.7]). 
 
One (0.2%) serotype Salmonella ser. Typhimurium isolate was resistant to both quinolones and third-generation 
cephalosporins in 2006. Since 1996, eight Salmonella ser. Typhimurium isolates have shown this multidrug 
resistance pattern. 
 
Table 1.08: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial agents, 2006 (N=407) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.9] 2.9 74.4 20.9 1.7
Gentamicin 0.2 2.7 [1.4–4.8] 60.0 34.6 2.5 0.2 1.0 1.7
Streptomycin NA 29.5 [25.1–34.2] 70.5 17.2 12.3
Aminopenicillins Ampicillin 0.0 28.3 [23.9–32.9] 61.4 10.1 0.2 28.3
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 14.5 4.4 [2.6–6.9] 69.8 2.0 0.7 8.6 14.5 0.2 4.2
Ceftiofur 0.0 4.2 [2.5–6.6] 0.5 48.9 45.7 0.7 4.2
Ceftriaxone 2.2 0.2 [0.0–1.4] 95.8 1.7 1.0 1.2 0.2
Ciprofloxacin 0.0 0.2 [0.0–1.4] 96.3 2.0 0.2 0.2 1.0 0.2
Nalidixic acid NA 0.7 [0.2–2.1] 0.2 48.4 49.1 0.7 0.7 0.7
Aminoglycosides Kanamycin 0.0 5.2 [3.2–7.8] 94.6 0.2 5.2
Cephamycins Cefoxitin 0.2 3.9 [2.3–6.3] 26.8 60.4 7.4 1.2 0.2 2.2 1.7
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 2.2 [1.0–4.2] 75.9 21.4 0.2 0.2 2.2
Phenicols Chloramphenicol 0.7 22.1 [18.2–26.5] 2.5 49.9 24.8 0.7 22.1
Sulfonamides Sulfisoxazole NA 33.4 [28.8–38.2] 11.3 51.6 3.7 33.4
Tetracyclines Tetracycline 0.0 31.7 [27.2–36.5] 68.3 3.9 13.0 14.7
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides































Table 1.09: Percentage and number of Salmonella ser. Typhimurium isolates resistant to antimicrobial 
agents, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0 0
Gentamicin 4.2% 4.6% 3.7% 2.2% 2.6% 1.5% 2.3% 2.0% 2.1% 1.8% 2.7%
(MIC ≥ 16) 13 15 14 8 8 5 9 8 8 8 11
Streptomycin 51.6% 55.2% 47.8% 43.3% 39.5% 40.1% 31.8% 35.2% 31.7% 27.9% 29.5%
(MIC ≥ 64) 158 181 182 157 120 130 125 143 121 122 120
Ampicillin 50.0% 50.3% 45.7% 41.3% 42.1% 42.6% 33.6% 36.0% 31.9% 28.8% 28.3%
(MIC ≥ 32) 153 165 174 150 128 138 132 146 122 126 115
Amoxicillin-clavulanic acid 2.6% 3.4% 4.5% 2.8% 6.3% 6.2% 7.6% 5.4% 4.7% 3.2% 4.4%
(MIC ≥ 32) 8 11 17 10 19 20 30 22 18 14 18
Ceftiofur 0.0% 1.5% 1.8% 1.9% 3.6% 3.1% 4.3% 4.9% 4.5% 2.5% 4.2%
(MIC ≥ 8) 0 5 7 7 11 10 17 20 17 11 17
Ceftriaxone 0.0% 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.2% 0.8% 0.0% 0.2%
(MIC ≥ 64) 0 1 0 1 0 0 1 1 3 0 1
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.2%
(MIC ≥ 4) 0 0 0 0 0 1 0 0 0 0 1
Nalidixic acid 0.3% 0.9% 0.5% 0.0% 1.3% 0.6% 1.3% 1.2% 0.5% 0.9% 0.7%
(MIC ≥ 32) 1 3 2 0 4 2 5 5 2 4 3
Aminoglycosides Kanamycin 14.4% 15.5% 15.7% 12.9% 13.2% 8.3% 7.6% 7.1% 5.8% 5.7% 5.2%
(MIC ≥ 64) 44 51 60 47 40 27 30 29 22 25 21
Cephalothin 2.0% 4.3% 3.9% 4.4% 4.3% 3.1% 5.6% 6.2% Not Not Not
(MIC ≥ 32) 6 14 15 16 13 10 22 25 Tested Tested Tested
Cefoxitin Not Not Not Not 3.6% 3.1% 4.3% 4.4% 4.7% 2.5% 3.9%
(MIC ≥ 32) Tested Tested Tested Tested 11 10 17 18 18 11 16
Trimethoprim-sulfamethoxazole 4.6% 3.0% 4.5% 2.8% 3.6% 2.5% 2.3% 3.4% 2.6% 2.7% 2.2%
(MIC ≥ 4) 14 10 17 10 11 8 9 14 10 12 9
Chloramphenicol 39.9% 36.0% 34.1% 28.9% 30.9% 31.8% 23.2% 27.8% 24.1% 24.3% 22.1%
(MIC ≥ 32) 122 118 130 105 94 103 91 113 92 106 90
Sulfamethoxazole/Sulfisoxazole† 53.3% 56.7% 50.1% 45.7% 45.4% 43.2% 32.1% 38.4% 35.9% 31.8% 33.4%
(MIC ≥ 512) 163 186 191 166 138 140 126 156 137 139 136
Tetracycline 49.3% 52.4% 46.5% 41.9% 43.4% 43.5% 31.8% 37.9% 30.1% 30.2% 31.7%
(MIC ≥ 16) 151 172 177 152 132 141 125 154 115 132 129
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 

















Table 1.10: Resistance patterns of Salmonella ser. Typhimurium isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 306 328 381 363 304 324 393 406 382 437 407
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 37.9% 39.0% 46.5% 50.4% 49.3% 49.1% 60.3% 54.9% 60.7% 65.2% 62.4%
 116 128 177 183 150 159 237 223 232 285 254
Resistance ≥ 1 CLSI subclass* 62.1% 61.0% 53.5% 49.6% 50.7% 50.9% 39.7% 45.1% 39.3% 34.8% 37.6%
 190 200 204 180 154 165 156 183 150 152 153
Resistance ≥ 2 CLSI subclasses* 56.2% 56.7% 51.4% 46.3% 47.0% 48.1% 36.1% 41.4% 37.2% 33.2% 34.2%
 172 186 196 168 143 156 142 168 142 145 139
Resistance ≥ 3 CLSI subclasses* 51.0% 52.4% 47.8% 43.3% 43.4% 42.0% 32.3% 36.9% 31.4% 30.0% 30.5%
 156 172 182 157 132 136 127 150 120 131 124
Resistance ≥ 4 CLSI subclasses* 45.4% 47.9% 43.3% 38.6% 39.8% 38.3% 28.5% 32.0% 28.0% 27.2% 27.3%
 139 157 165 140 121 124 112 130 107 119 111
Resistance ≥ 5 CLSI subclasses* 35.6% 36.0% 34.6% 28.1% 30.6% 29.9% 23.4% 27.8% 24.3% 23.6% 21.9%
 109 118 132 102 93 97 92 113 93 103 89
At least ACSSuT† 33.7% 35.1% 32.5% 27.8% 28.0% 29.6% 21.4% 26.1% 23.3% 22.2% 19.7%
 103 115 124 101 85 96 84 106 89 97 80
At least ACSuTm‡ 2.0% 0.6% 2.6% 2.2% 1.6% 0.9% 2.0% 3.2% 1.6% 2.1% 0.7%
 6 2 10 8 5 3 8 13 6 9 3
At least ACSSuTAuCf§ 0.0% 1.2% 1.0% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6% 1.8% 2.9%
 0 4 4 2 6 4 7 9 10 8 12
At least MDR-AmpC¶ 0.0% 1.2% 1.0% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6% 1.8% 2.9%
 0 4 4 2 6 4 7 9 10 8 12
Resistance to quinolone** and cephalosporin†† 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.5% 0.0% 0.3% 0.2% 0.2%
 0 1 0 0 1 1 2 0 1 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)




C. Salmonella ser. Newport 
 
In 2006, Newport was the third most common non-Typhi Salmonella serotype in NARMS.  The MDR-AmpC 
phenotype in Salmonella ser. Newport increased from 1996 to 2006. The MDR-AmpC phenotype was first noted 
in 1998, increased to 18.2% in 1999, peaked at 25.0% in 2001, and declined to 10.6% in 2006. A similar trend 
was observed for ceftiofur resistance. 
 
In 2006, Salmonella ser. Newport was the third most commonly isolated non-Typhi Salmonella serotype in 
NARMS, accounting for 9.9% (217/2,184) of non-Typhi Salmonella isolates (Table 1.04). Salmonella ser. Newport 
isolates were most commonly resistant to ampicillin and sulfisoxazole (15.2%), tetracycline (14.3%), streptomycin 
(13.8%), cefoxitin (12.9%), and ceftiofur, chloramphenicol, and amoxicillin-clavulanic acid (12.4%) (Table 1.12). 
The prevalence of resistance among clinically important antimicrobial subclasses was 0.5% for quinolones 
(represented by nalidixic acid) and 12.4% for third-generation cephalosporins (represented by ceftiofur).
 
Ceftiofur resistance was first noted in one isolate (1.3%) in 1998; it increased to 18.2% in 1999, peaked at 27.4% 
in 2001, and declined to 12.4% in 2006 (Table 1.12). Salmonella ser. Newport was the most prevalent (34.2%) 
non-Typhi Salmonella serotype that showed resistance to ceftiofur (Table 1.20).  
 
While the percentage of Salmonella ser. Newport isolates with no detected resistance declined from 86.3% in 
1996 to 65.3% in 2001 (Table 1.13) resistance increased to 82.9% in 2006. Resistance to at least five subclasses 
of antimicrobial agents increased from 5.9% in 1996 to 12.9% in 2006 and peaked at 27.4% in 2001.   
 
In 2006, the most common multidrug-resistant phenotype among Salmonella ser. Newport was at least ACSSuT 
(12.0% of isolates).  Among these, most also showed resistance to amoxicillin-clavulanate and ceftiofur and 
decreased susceptibility (MIC ≥2 µg/mL) to ceftriaxone (the MDR-AmpC phenotype). Isolates that showed the 
MDR-AmpC phenotype comprised 10.6% of Newport submissions in 2006. MDR-AmpC resistance followed the 
same pattern as ceftiofur resistance (Table 1.13); it increased from 0% in 1996 to 18.2% in 1999, peaked at 
25.0% in 2001, and declined to 10.6% in 2006. In the logistic regression model, the increase from 1996 to 2006 
was statistically significant (95% CI [1.4, infinity]). 
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Table 1.11: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Newport isolates 
to antimicrobial agents, 2006 (N=217) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.7] 7.4 78.3 13.4 0.5 0.5
Gentamicin 0.5 0.9 [0.1–3.3] 67.7 30.4 0.5 0.5 0.5 0.5
Streptomycin NA 13.8 [9.5–19.1] 86.2 0.9 12.9
Aminopenicillins Ampicillin 0.0 15.2 [10.7–20.7] 77.0 6.9 0.9 15.2
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.9 12.4 [8.4–17.6] 82.0 2.3 0.5 1.8 0.9 6.5 6.0
Ceftiofur 0.0 12.4 [8.4–17.6] 0.5 45.2 40.1 1.8 12.4
Ceftriaxone 12.0 0.5 [0.0–2.5] 87.1 0.5 5.1 6.9 0.5
Ciprofloxacin 0.0 0.0 [0.0–1.7] 99.1 0.5 0.5
Nalidixic acid NA 0.5 [0.0–2.5] 0.5 44.7 53.9 0.5 0.5
Aminoglycosides Kanamycin 0.5 2.3 [0.8–5.3] 96.8 0.5 0.5 2.3
Cephamycins Cefoxitin 0.0 12.9 [8.7–18.1] 0.5 23.0 58.1 4.1 1.4 2.3 10.6
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 3.2 [1.3–6.5] 87.6 8.3 0.5 0.5 3.2
Phenicols Chloramphenicol 0.5 12.4 [8.4–17.6] 1.8 76.0 9.2 0.5 12.4
Sulfonamides Sulfisoxazole NA 15.2 [10.7–20.7] 6.0 38.7 40.1 15.2
Tetracyclines Tetracycline 0.0 14.3 [9.9–19.7] 85.7 3.7 10.6
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides































Table 1.12: Percentage and number of Salmonella ser. Newport isolates resistant to antimicrobial agents, 
1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0 0
Gentamicin 5.9% 4.3% 0.0% 0.0% 2.5% 3.2% 3.3% 3.1% 0.5% 1.0% 0.9%
(MIC ≥ 16) 3 2 0 0 3 4 8 7 1 2 2
Streptomycin 7.8% 4.3% 2.6% 19.2% 24.0% 31.5% 25.3% 24.2% 15.7% 14.0% 13.8%
(MIC ≥ 64) 4 2 2 19 29 39 61 54 30 29 30
Ampicillin 5.9% 6.5% 2.6% 18.2% 23.1% 29.8% 24.9% 22.9% 15.7% 14.0% 15.2%
(MIC ≥ 32) 3 3 2 18 28 37 60 51 30 29 33
Amoxicillin-clavulanic acid 2.0% 0.0% 2.6% 18.2% 22.3% 26.6% 22.8% 21.5% 15.2% 12.6% 12.4%
(MIC ≥ 32) 1 0 2 18 27 33 55 48 29 26 27
Ceftiofur 0.0% 0.0% 1.3% 18.2% 22.3% 27.4% 22.8% 22.0% 15.2% 12.6% 12.4%
(MIC ≥ 8) 0 0 1 18 27 34 55 49 29 26 27
Ceftriaxone 0.0% 0.0% 0.0% 3.0% 0.0% 0.0% 0.8% 1.8% 2.6% 1.4% 0.5%
(MIC ≥ 64) 0 0 0 3 0 0 2 4 5 3 1
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.8% 0.4% 0.5% 0.0% 0.5%
(MIC ≥ 32) 0 0 0 0 1 0 2 1 1 0 1
Aminoglycosides Kanamycin 2.0% 0.0% 1.3% 1.0% 5.0% 7.3% 10.0% 4.5% 2.6% 1.9% 2.3%
(MIC ≥ 64) 1 0 1 1 6 9 24 10 5 4 5
Cephalothin 3.9% 4.3% 2.6% 18.2% 22.3% 26.6% 22.8% 22.4% Not Not Not
(MIC ≥ 32) 2 2 2 18 27 33 55 50 Tested Tested Tested
Cefoxitin Not Not Not Not 22.3% 25.8% 22.4% 21.5% 15.2% 12.6% 12.9%
(MIC ≥ 32) Tested Tested Tested Tested 27 32 54 48 29 26 28
Trimethoprim-sulfamethoxazole 3.9% 4.3% 1.3% 2.0% 4.1% 1.6% 4.1% 0.9% 2.1% 1.9% 3.2%
(MIC ≥ 4) 2 2 1 2 5 2 10 2 4 4 7
Chloramphenicol 5.9% 4.3% 2.6% 18.2% 23.1% 28.2% 25.3% 22.4% 15.2% 13.5% 12.4%
(MIC ≥ 32) 3 2 2 18 28 35 61 50 29 28 27
Sulfamethoxazole/Sulfisoxazole† 11.8% 4.3% 3.9% 22.2% 23.1% 32.3% 25.7% 24.7% 16.8% 15.5% 15.2%
(MIC ≥ 512) 6 2 3 22 28 40 62 55 32 32 33
Tetracycline 7.8% 4.3% 2.6% 19.2% 23.1% 30.6% 25.7% 24.2% 16.8% 14.5% 14.3%
(MIC ≥ 16) 4 2 2 19 28 38 62 54 32 30 31
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 


















Table 1.13: Resistance patterns of Salmonella ser. Newport isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 51 46 77 99 121 124 241 223 191 207 217
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 86.3% 93.5% 94.8% 75.8% 75.2% 65.3% 72.2% 73.5% 82.2% 84.1% 82.9%
 44 43 73 75 91 81 174 164 157 174 180
Resistance ≥ 1 CLSI subclass* 13.7% 6.5% 5.2% 24.2% 24.8% 34.7% 27.8% 26.5% 17.8% 15.9% 17.1%
 7 3 4 24 30 43 67 59 34 33 37
Resistance ≥ 2 CLSI subclasses* 7.8% 4.3% 2.6% 18.2% 23.1% 32.3% 25.7% 25.1% 17.3% 15.0% 16.1%
 4 2 2 18 28 40 62 56 33 31 35
Resistance ≥ 3 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 25.3% 23.3% 16.8% 14.5% 14.7%
 3 2 2 18 28 39 61 52 32 30 32
Resistance ≥ 4 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 25.3% 22.9% 15.7% 14.0% 13.8%
 3 2 2 18 28 39 61 51 30 29 30
Resistance ≥ 5 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 27.4% 23.7% 22.4% 14.7% 12.6% 12.9%
 3 2 2 18 28 34 57 50 28 26 28
At least ACSSuT† 5.9% 4.3% 1.3% 18.2% 23.1% 25.8% 23.7% 22.0% 14.7% 12.6% 12.0%
 3 2 1 18 28 32 57 49 28 26 26
At least ACSuTm‡ 3.9% 4.3% 1.3% 2.0% 4.1% 0.8% 3.7% 0.9% 1.0% 1.9% 2.3%
 2 2 1 2 5 1 9 2 2 4 5
At least ACSSuTAuCf§ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.8% 21.1% 14.7% 12.6% 10.6%
 0 0 1 18 27 31 55 47 28 26 23
At least MDR-AmpC¶ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.8% 21.1% 14.7% 12.6% 10.6%
 0 0 1 18 27 31 55 47 28 26 23
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 1.3% 0.0% 0.0% 0.0% 0.4% 0.0% 0.5% 0.0% 0.5%
 0 0 1 0 0 0 1 0 1 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)
**Resistance to nalidixic acid (MIC ≥ 32) or decreased susceptibility to ciprofloxacin (MIC ≥ 0.12)
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D. Salmonella ser. I 4,[5],12:i:- 
 
In 2006, Salmonella ser. I 4,[5],12:i:- was the fourth most common non-Typhi Salmonella serotype in NARMS.  
Most Salmonella ser. I 4,[5],12:i:-  isolates had no detected resistance and multidrug resistance was rare. 
 
In 2006, Salmonella ser. I 4,[5],12:i:- was the fourth most commonly isolated non-Typhi Salmonella serotype in 
NARMS, accounting for 4.8% (105/2,184) of non-Typhi Salmonella isolates (Table 1.04). In 2005, I 4,[5],12:i:- was 
the 12th most commonly reported serotype among NARMS submissions, making up 1.6% of the non-Typhi 
Salmonella. Salmonella ser. I 4,[5],12:i:- isolates were most commonly resistant to sulfisoxazole and tetracycline 
(8.6%), ampicillin (6.7%), gentamicin (4.8%), streptomycin, amoxicillin-clavulanic acid, ceftiofur, and cefoxitin 
(3.8%) (Table 1.15). The prevalence of resistance among clinically important antimicrobial subclasses was 1.7% 
for quinolones (represented by nalidixic acid) and 5.1% for third-generation cephalosporins (represented by 
ceftiofur) (Table 1.20).
 
Most I 4,[5],12:i:-  isolates had no detected resistance. The percentage of  I 4,[5],12:i:-  isolates with no detected 
resistance increased from 80.6% in 2004 to 87.9% in 2005, but has slightly decreased to 85.7% in 2006 (Table 
1.16). 
 
Multidrug-resistance was not common among I 4,[5],12:i:- isolates (Table 1.16). However, 2 isolates (1.9%) with 
resistance to at least ACSSuT were identified in 2006.  
 
Table 1.14: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. I 4,[5],12:i:- 
isolates to antimicrobial agents, 2006 (N=105) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–3.5] 2.9 75.2 20.0 1.9
Gentamicin 0.0 4.8 [1.6–10.8] 59.0 36.2 3.8 1.0
Streptomycin NA 3.8 [1.0–9.5] 96.2 1.9 1.9
Aminopenicillins Ampicillin 0.0 6.7 [2.7–13.3] 87.6 5.7 6.7
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 1.0 3.8 [1.0–9.5] 93.3 1.9 1.0 3.8
Ceftiofur 0.0 3.8 [1.0–9.5] 1.0 67.6 27.6 3.8
Ceftriaxone 3.8 0.0 [0.0–3.5] 96.2 3.8
Ciprofloxacin 0.0 0.0 [0.0–3.5] 97.1 1.9 1.0
Nalidixic acid NA 1.0 [0.0–5.2] 70.5 28.6 1.0
Aminoglycosides Kanamycin 0.0 0.0 [0.0–3.5] 100.0
Cephamycins Cefoxitin 0.0 3.8 [1.0–9.5] 1.0 48.6 46.7 3.8
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.0 [0.0–3.5] 95.2 4.8
Phenicols Chloramphenicol 0.0 1.9 [0.2–6.7] 84.8 13.3 1.9
Sulfonamides Sulfisoxazole NA 8.6 [4.0–15.6] 11.4 65.7 14.3 8.6
Tetracyclines Tetracycline 0.0 8.6 [4.0–15.6] 91.4 1.9 1.9 4.8
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides






























Table 1.15: Percentage and number of Salmonella ser. I 4,[5],12:i:- isolates resistant to antimicrobial 
agents, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 7.1% 0.0% 5.4% 5.6% 0.0% 4.8%
(MIC ≥ 16) 0 0 0 0 1 0 2 2 0 5
Streptomycin 0.0% 66.7% 0.0% 7.7% 14.3% 2.9% 8.1% 5.6% 3.0% 3.8%
(MIC ≥ 64) 0 2 0 1 2 1 3 2 1 4
Ampicillin 0.0% 0.0% 0.0% 7.7% 7.1% 8.6% 8.1% 5.6% 6.1% 6.7%
(MIC ≥ 32) 0 0 0 1 1 3 3 2 2 7
Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.0% 0.0% 2.9% 5.4% 2.8% 3.0% 3.8%
(MIC ≥ 32) 0 0 0 0 0 1 2 1 1 4
Ceftiofur 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 5.4% 2.8% 3.0% 3.8%
(MIC ≥ 8) 0 0 0 0 1 1 2 1 1 4
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.8% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 1 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.7% 2.8% 0.0% 1.0%
(MIC ≥ 32) 0 0 0 0 0 0 1 1 0 1
Aminoglycosides Kanamycin 0.0% 0.0% 0.0% 0.0% 7.1% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 1 0 0 0 0 0
Cephalothin 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 5.4% Not Not Not
(MIC ≥ 32) 0 0 0 0 1 1 2 Tested Tested Tested
Cefoxitin Not Not Not 0.0% 0.0% 2.9% 5.4% 2.8% 3.0% 3.8%
(MIC ≥ 32) Tested Tested Tested 0 0 1 2 1 1 4
Trimethoprim-sulfamethoxazole 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 1 1 0 1 0 0
Chloramphenicol 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 1.9%
(MIC ≥ 32) 0 0 0 0 1 1 0 1 0 2
Sulfamethoxazole/Sulfisoxazole† 0.0% 100.0% 12.5% 0.0% 14.3% 2.9% 5.4% 11.1% 0.0% 8.6%
(MIC ≥ 512) 0 3 1 0 2 1 2 4 0 9
Tetracycline 0.0% 0.0% 0.0% 7.7% 7.1% 5.7% 0.0% 11.1% 3.0% 8.6%
(MIC ≥ 16) 0 0 0 1 1 2 0 4 1 9











*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 









Table 1.16: Resistance patterns of Salmonella ser. I 4,[5],12:i:- isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 3 3 0 8 13 14 35 37 36 33 105
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 100.0% 0.0% 87.5% 92.3% 78.6% 91.4% 78.4% 80.6% 87.9% 85.7%
 3 0 7 12 11 32 29 29 29 90
Resistance ≥ 1 CLSI subclass* 0.0% 100.0% 12.5% 7.7% 21.4% 8.6% 21.6% 19.4% 12.1% 14.3%
 0 3 1 1 3 3 8 7 4 15
Resistance ≥ 2 CLSI subclasses* 0.0% 66.7% 0.0% 7.7% 14.3% 8.6% 10.8% 13.9% 3.0% 11.4%
 0 2 0 1 2 3 4 5 1 12
Resistance ≥ 3 CLSI subclasses* 0.0% 0.0% 0.0% 7.7% 7.1% 5.7% 5.4% 11.1% 3.0% 9.5%
 0 0 0 1 1 2 2 4 1 10
Resistance ≥ 4 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 3.8%
 0 0 0 0 1 1 0 1 0 4
Resistance ≥ 5 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 2.9%
 0 0 0 0 1 1 0 1 0 3
At least ACSSuT† 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0% 1.9%
 0 0 0 0 1 1 0 1 0 2
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 0 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)
**Resistance to nalidixic acid (MIC ≥ 32) or decreased susceptibility to ciprofloxacin (MIC ≥ 0.12)
 
 
E. Salmonella ser. Heidelberg 
 
In 2006, Salmonella ser. Heidelberg was the fifth most commonly isolated non-Typhi Salmonella serotype in 
NARMS, accounting for 4.7% (102/2,184) of non-Typhi Salmonella isolates (Table 1.04). Serotype Heidelberg 
isolates were most commonly resistant to ampicillin (18.6%), tetracycline (13.7%), streptomycin (11.8%), 
amoxicillin-clavulanic acid and ceftiofur (9.8%), kanamycin and cefoxitin (8.8%), and sulfisoxazole and gentamicin 
(4.9%) (Table 1.18). 
 
Ceftiofur resistance was first noted in one isolate (1.4%) in 1996. Resistance increased to ten isolates (9.8%) in 
2006 (Table 1.18). Heidelberg was the third most common serotype (12.7%) among ceftiofur-resistant non-Typhi 
Salmonella (Table 1.20).  
 
In contrast to other common serotypes, the percentage of Heidelberg isolates with no detected resistance 
increased from 54.1% in 1996 to 67.6% in 2006 (Table 1.19). In addition, resistance to at least five CLSI 




Table 1.17: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial agents, 2006 (N=102) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–3.6] 17.6 64.7 16.7 1.0
Gentamicin 1.0 4.9 [1.6–11.1] 66.7 25.5 1.0 1.0 1.0 2.0 2.9
Streptomycin NA 11.8 [6.2–19.6] 88.2 8.8 2.9
Aminopenicillins Ampicillin 0.0 18.6 [11.6–27.6] 70.6 8.8 2.0 18.6
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 2.0 9.8 [4.8–17.3] 76.5 3.9 1.0 6.9 2.0 4.9 4.9
Ceftiofur 0.0 9.8 [4.8–17.3] 56.9 32.4 1.0 1.0 8.8
Ceftriaxone 7.8 0.0 [0.0–3.6] 90.2 1.0 1.0 5.9 2.0
Ciprofloxacin 0.0 0.0 [0.0–3.6] 98.0 2.0
Nalidixic acid NA 0.0 [0.0–3.6] 24.5 75.5
Aminoglycosides Kanamycin 0.0 8.8 [4.1–16.1] 90.2 1.0 8.8
Cephamycins Cefoxitin 1.0 8.8 [4.1–16.1] 52.9 33.3 2.9 1.0 1.0 5.9 2.9
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.0 [0.0–3.6] 94.1 5.9
Phenicols Chloramphenicol 1.0 0.0 [0.0–3.6] 60.8 38.2 1.0
Sulfonamides Sulfisoxazole NA 4.9 [1.6–11.1] 36.3 50.0 7.8 1.0 4.9
Tetracyclines Tetracycline 0.0 13.7 [7.7–22.0] 86.3 1.0 1.0 11.8
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides





























Table 1.18: Percentage and number of Salmonella ser. Heidelberg isolates resistant to antimicrobial 
agents, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0 0
Gentamicin 23.0% 17.3% 16.8% 14.8% 8.9% 7.8% 3.8% 5.2% 4.3% 6.4% 4.9%
(MIC ≥ 16) 17 13 17 13 7 8 4 5 4 8 5
Streptomycin 40.5% 24.0% 30.7% 23.9% 22.8% 25.5% 17.1% 12.5% 15.1% 13.6% 11.8%
(MIC ≥ 64) 30 18 31 21 18 26 18 12 14 17 12
Ampicillin 14.9% 13.3% 16.8% 6.8% 10.1% 9.8% 12.4% 10.4% 25.8% 20.0% 18.6%
(MIC ≥ 32) 11 10 17 6 8 10 13 10 24 25 19
Amoxicillin-clavulanic acid 2.7% 1.3% 1.0% 1.1% 3.8% 2.9% 9.5% 5.2% 10.8% 8.8% 9.8%
(MIC ≥ 32) 2 1 1 1 3 3 10 5 10 11 10
Ceftiofur 1.4% 0.0% 0.0% 0.0% 3.8% 2.9% 7.6% 5.2% 9.7% 8.8% 9.8%
(MIC ≥ 8) 1 0 0 0 3 3 8 5 9 11 10
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 1.0% 1.1% 1.3% 0.0% 0.0% 1.0% 0.0% 0.8% 0.0%
(MIC ≥ 32) 0 0 1 1 1 0 0 1 0 1 0
Aminoglycosides Kanamycin 14.9% 8.0% 12.9% 9.1% 15.2% 19.6% 10.5% 8.3% 8.6% 12.8% 8.8%
(MIC ≥ 64) 11 6 13 8 12 20 11 8 8 16 9
Cephalothin 6.8% 2.7% 5.9% 3.4% 5.1% 3.9% 10.5% 7.3% Not Not 0.0%
(MIC ≥ 32) 5 2 6 3 4 4 11 7 Tested Tested 0
Cefoxitin Not Not Not Not 2.5% 2.9% 8.6% 5.2% 8.6% 8.8% 8.8%
(MIC ≥ 32) Tested Tested Tested Tested 2 3 9 5 8 11 9
Trimethoprim-sulfamethoxazole 0.0% 0.0% 2.0% 1.1% 1.3% 2.0% 1.0% 2.1% 0.0% 0.8% 0.0%
(MIC ≥ 4) 0 0 2 1 1 2 1 2 0 1 0
Chloramphenicol 1.4% 0.0% 1.0% 1.1% 1.3% 1.0% 1.0% 0.0% 1.1% 0.8% 0.0%
(MIC ≥ 32) 1 0 1 1 1 1 1 0 1 1 0
Sulfamethoxazole/Sulfisoxazole† 17.6% 21.3% 21.8% 18.2% 11.4% 8.8% 6.7% 7.3% 7.5% 8.0% 4.9%
(MIC ≥ 512) 13 16 22 16 9 9 7 7 7 10 5
Tetracycline 20.3% 12.0% 19.8% 18.2% 21.5% 24.5% 19.0% 16.7% 19.4% 18.4% 13.7%
(MIC ≥ 16) 15 9 20 16 17 25 20 16 18 23 14
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 


















Table 1.19: Resistance patterns of Salmonella ser. Heidelberg isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 74 75 101 88 79 102 105 96 93 125 102
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 54.1% 66.7% 56.4% 68.2% 63.3% 64.7% 67.6% 68.8% 55.9% 62.4% 67.6%
 40 50 57 60 50 66 71 66 52 78 69
Resistance ≥ 1 CLSI subclass* 45.9% 33.3% 43.6% 31.8% 36.7% 35.3% 32.4% 31.3% 44.1% 37.6% 32.4%
 34 25 44 28 29 36 34 30 41 47 33
Resistance ≥ 2 CLSI subclasses* 33.8% 26.7% 33.7% 26.1% 26.6% 29.4% 25.7% 17.7% 23.7% 24.8% 23.5%
 25 20 34 23 21 30 27 17 22 31 24
Resistance ≥ 3 CLSI subclasses* 12.2% 12.0% 13.9% 10.2% 7.6% 7.8% 11.4% 10.4% 14.0% 15.2% 12.7%
 9 9 14 9 6 8 12 10 13 19 13
Resistance ≥ 4 CLSI subclasses* 4.1% 1.3% 4.0% 4.5% 3.8% 2.0% 1.9% 2.1% 4.3% 4.8% 2.0%
 3 1 4 4 3 2 2 2 4 6 2
Resistance ≥ 5 CLSI subclasses* 2.7% 1.3% 1.0% 0.0% 3.8% 2.0% 1.9% 0.0% 3.2% 2.4% 2.0%
 2 1 1 0 3 2 2 0 3 3 2
At least ACSSuT† 1.4% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 1.1% 0.0% 0.0%
 1 0 0 0 1 1 1 0 1 0 0
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 1 0 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 1 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 1 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.8% 0.0%
 0 0 0 0 0 0 0 0 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)





F. Specific Drug Resistance Phenotypes 
 
The multidrug–resistant phenotypes ACSSuT, MDR-AmpC, and resistance to nalidixic acid and Ceftiofur were 
detected in several other serotypes in 2006 (Table 1.20). 
 
In 2006, 121 (5.5%) non-Typhi Salmonella isolates were resistant to at least ACSSuT. Of these isolates, 66.1% 
were serotype Typhimurium; 21.5% Newport; 3.3% Agona; 2.5% Paratyphi B var. L(+) tartrate+; 1.7%  
I 4,[5],12:i:-; and 0.8% were serotypes Saintpaul, Stanley, and Tennessee (Table 1.20). Forty-three (2.0%) non-
Typhi Salmonella isolates were resistant to at least MDR-AmpC of which 53.5% were serotype Newport; 27.9% 
Typhimurium; 9.3% Agona; and 2.3% Saintpaul. Sixty (2.7%) non-Typhi Salmonella isolates were nalidixic acid 
resistant, 48.3% of which were Enteritidis; 5.0% Typhimurium; and 1.7% for serotypes Newport, I 4,[5],12:i:-, 
Muenchen, Agona, Braenderup, Stanley, Hadar, and Tennessee. Seventy-nine (3.6%) non-Typhi Salmonella 
isolates were ceftiofur resistant, of which 34.2% were serotype Newport; 21.5% Typhimurium; 12.7%  Heidelberg; 
6.3%  Agona; 5.1% I 4[5]12:i:- and 2.5% Enteritidis.
 
 
Table 1.20: Number and percentage of ACSSuT-, MDR-AmpC-, nalidixic acid-, and ceftiofur-resistant 
isolates among the 20 most common non-Typhi Salmonella serotypes isolated in NARMS, 2006 
Rank Serotype N n (%) n (%) n (%) n (%)
1 Enteritidis 412 0 (0.0%) 0 (0.0%) 29 (48.3%) 2 (2.5%)
2 Typhimurium 407 80 (66.1%) 12 (27.9%) 3 (5.0%) 17 (21.5%)
3 Newport 217 26 (21.5%) 23 (53.5%) 1 (1.7%) 27 (34.2%)
4 I 4,[5],12:i:-  105 2 (1.7%) 0 (0.0%) 1 (1.7%) 4 (5.1%)
5 Heidelberg 102 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (12.7%)
6 Javiana 80 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
7 Montevideo 62 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
8 Paratyphi B var. L(+) tartrate+ 49 3 (2.5%) 0 (0.0%) 0 (0.0%) 1 (1.3%)
9 Oranienburg 48 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
10 Muenchen 45 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
11 Agona 42 4 (3.3%) 4 (9.3%) 1 (1.7%) 5 (6.3%)
12 Saintpaul 30 1 (0.8%) 1 (2.3%) 0 (0.0%) 1 (1.3%)
13 Braenderup 29 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
14 Thompson 26 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%)
15 Stanley 25 1 (0.8%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
16 Mississippi 24 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
17 Infantis 22 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
18 Hadar 22 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
19 Tennessee 21 1 (0.8%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
20 Berta 19 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%)
Subtotal 1787 118 (97.5%) 40 (93.0%) 40 (66.7%) 69 (87.3%)
All Other Serotypes 397 3 (2.5%) 3 (7.0%) 20 (33.3%) 10 0.0%
Total 2184 121 (100.0%) 43 (100.0%) 60 (100.0%) 79 (100.0%)
*ACSSuT: ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline
† MDR-AmpC: ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2µg/mL)






2. Salmonella ser. Typhi 
 
Among Salmonella ser. Typhi isolates, resistance to nalidixic acid increased from 19.2% in 1999 to 54.0% in 
2006. Resistance to most of the antimicrobial agents tested increased from 2005 to 2006. The percentage of 
isolates with no detected resistance decreased from 48.1% in 2005 to 40.4% in 2006. 
 
During 2006, Salmonella ser. Typhi were most commonly resistant to nalidixic acid (54.0%), trimethoprim-
sulfamethoxazole, sulfisoxazole, and ampicillin (20.7%), chloramphenicol (19.4%), and streptomycin (18.8%) 
(Table 2.02). Resistance to most of the antimicrobial agents tested increased from 2005 to 2006 (Table 2.02).  
Nalidixic acid resistance increased from 19.2% in 1999 to 54.0% in 2006; a statistically significant increase 
(OR=5.2, 95% CI [3.3, 8.1]).  Ciprofloxacin resistance increased from 0.3% in 2005 to 0.9% in 2006. 
 
The percentage of isolates with no detected resistance decreased from 48.1% in 2005 to 40.4% in 2006. 
Resistance to greater than five CLSI subclasses increased from 11.9% in 2005 to 16.4% in 2006.  Salmonella ser. 
Typhi isolates with the resistance phenotype ACSuTm increased from 12.6 % to 18.5% between 1999 and 2006 
(Table 2.03). A single isolate exhibited both quinolone and third-generation cephalosporin resistance in 2006. 
 
Table 2.01: Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2006 (N=324) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.1] 25.9 69.8 4.0 0.3
Gentamicin 0.0 0.0 [0.0–1.1] 95.7 4.0 0.3
Streptomycin NA 18.8 [14.7–23.5] 81.2 0.3 18.5
Aminopenicillins Ampicillin 0.0 20.7 [16.4–25.5] 69.1 9.3 0.9 0.3 20.4
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.3 0.3 [0.0–1.7] 78.1 0.6 7.7 13.0 0.3 0.3
Ceftiofur 0.0 0.0 [0.0–1.1] 0.9 9.3 80.2 9.0 0.6
Ceftriaxone 0.0 0.0 [0.0–1.1] 100.0
Ciprofloxacin 0.0 0.9 [0.2–2.7] 42.9 0.3 2.2 11.7 39.5 2.5 0.9
Nalidixic acid NA 54.0 [48.4–59.5] 0.3 2.8 37.7 3.7 1.2 0.3 0.6 53.4
Aminoglycosides Kanamycin 0.0 0.0 [0.0–1.1] 100.0
Cephamycins Cefoxitin 0.0 0.3 [0.0–1.7] 3.1 31.5 13.0 44.4 7.7 0.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 20.7 [16.4–25.5] 73.1 6.2 0.3 20.4
Phenicols Chloramphenicol 0.6 19.4 [15.3–24.2] 3.4 64.2 12.3 0.6 19.4
Sulfonamides Sulfisoxazole NA 20.7 [16.4–25.5] 38.3 24.7 13.3 3.1 20.7
Tetracyclines Tetracycline 0.0 8.3 [5.6–11.9] 91.7 8.3
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides






























Table 2.02: Percentage and number of Salmonella ser. Typhi isolates resistant to antimicrobial agents, 
1999–2006
Year 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 0 0 0 0
Streptomycin 13.8% 9.0% 20.3% 7.2% 14.4% 11.8% 13.2% 18.8%
(MIC ≥ 64) 23 16 40 14 48 36 42 61
Ampicillin 13.2% 9.0% 20.3% 5.6% 16.2% 11.8% 13.2% 20.7%
(MIC ≥ 32) 22 16 40 11 54 36 42 67
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.3%
(MIC ≥ 32) 1 0 0 0 1 0 0 1
Ceftiofur 0.6% 0.0% 0.0% 0.0% 0.6% 0.0% 0.0% 0.0%
(MIC ≥ 8) 1 0 0 0 2 0 0 0
Ceftriaxone 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0%
(MIC ≥ 64) 1 0 0 0 1 0 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.3% 0.9%
(MIC ≥ 4) 0 0 0 0 1 0 1 3
Nalidixic acid 19.2% 22.0% 29.9% 23.6% 37.7% 41.8% 48.4% 54.0%
(MIC ≥ 32) 32 39 59 46 126 127 154 175
Aminoglycosides Kanamycin 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 0 0 0 0 0
Cephalothin 2.4% 1.1% 0.5% 1.5% 0.6% Not Not Not
(MIC ≥ 32) 4 2 1 3 2 Tested Tested Tested
Cefoxitin Not 0.6% 0.5% 0.0% 0.9% 0.0% 0.0% 0.3%
(MIC ≥ 32) Tested 1 1 0 3 0 0 1
Trimethoprim-sulfamethoxazole 13.2% 9.0% 20.8% 6.7% 16.8% 13.2% 14.5% 20.7%
(MIC ≥ 4) 22 16 41 13 56 40 46 67
Chloramphenicol 12.6% 10.7% 20.8% 6.2% 16.5% 13.2% 13.2% 19.4%
(MIC ≥ 32) 21 19 41 12 55 40 42 63
Sulfamethoxazole/Sulfisoxazole† 16.8% 11.3% 20.8% 6.2% 17.1% 11.8% 14.2% 20.7%
(MIC ≥ 512) 28 20 41 12 57 36 45 67
Tetracycline 9.6% 9.6% 20.8% 6.7% 15.6% 8.9% 10.1% 8.3%
(MIC ≥ 16) 16 17 41 13 52 27 32 27
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by 

















Table 2.03: Resistance patterns of Salmonella ser. Typhi isolates, 1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 167 177 197 195 334 304 318 324
% % % % % % % %
n n n n n n n n
No resistance detected 71.3% 72.9% 59.4% 74.4% 56.6% 56.6% 48.1% 40.4%
 119 129 117 145 189 172 153 131
Resistance ≥ 1 CLSI subclass* 28.7% 27.1% 40.6% 25.6% 43.4% 43.4% 51.9% 59.6%
 48 48 80 50 145 132 165 193
Resistance ≥ 2 CLSI subclasses* 15.0% 10.7% 22.8% 7.2% 18.0% 13.2% 14.5% 21.6%
 25 19 45 14 60 40 46 70
Resistance ≥ 3 CLSI subclasses* 13.2% 9.6% 22.8% 6.7% 17.7% 12.8% 13.8% 20.4%
 22 17 45 13 59 39 44 66
Resistance ≥ 4 CLSI subclasses* 13.2% 9.0% 21.8% 6.7% 16.8% 12.5% 12.9% 19.1%
 22 16 43 13 56 38 41 62
Resistance ≥ 5 CLSI subclasses* 12.6% 9.0% 18.8% 5.6% 15.9% 11.8% 11.9% 16.4%
 21 16 37 11 53 36 38 53
At least ACSSuT† 9.6% 7.9% 16.8% 5.6% 12.6% 7.9% 9.1% 5.9%
 16 14 33 11 42 24 29 19
At least ACSuTm‡ 12.6% 9.0% 17.8% 5.6% 15.6% 11.8% 12.9% 18.5%
 21 16 35 11 52 36 41 60
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.3%
 0 0 0 0 1 0 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)






In 2006, Shigella sonnei isolates showed a higher prevalence of resistance to streptomycin compared to Shigella 
flexneri.  S. flexneri showed a higher prevalence of resistance to tetracycline, sulfisoxazole, ampicillin, 
trimethoprim-sulfamethoxazole, and chloramphenicol compared to S. sonnei.  The percentage of isolates with no 
detected resistance was low in S. sonnei (4.7%) and S. flexneri (5.4%). 
 
During 2006, 402 Shigella isolates were tested, of which 321 (79.9%) were S. sonnei; 74 (18.7%), S. flexneri; 4 
(1.0%), S. boydii; and 2 (0.5%), S. dysenteriae (Table 3.01). Resistance was highest to ampicillin (62.2%), 
streptomycin (60.7%), trimethoprim-sulfamethoxazole (58.2%), sulfisoxazole (40.3%), and tetracycline (34.6%) 
(Table 3.02). Among all Shigella spp., resistance decreased from 2005 to 2006 to most of the antimicrobials 
tested. Ampicillin resistance decreased from 70.7% in 2005 to 62.2% in 2006; streptomycin resistance decreased 
from 68.7% to 60.7%; and sulfisoxazole resistance decreased from 57.6% to 40.3%.  Resistance to at least five 
CLSI subclasses declined from 1999 to 2006:  40.5% were resistant to at least five subclasses in 1999, compared 
with 13.7% in 2006 (Table 3.08). Resistance to trimethoprim-sulfamethoxazole increased from 51.5% in 1999 to 
58.2% in 2006.  One isolate in 2006 exhibited resistance to ciprofloxacin, making this the second ciprofloxacin 
resistant isolate since 1999.  Of isolates tested in all years from 1999 to 2006, more than 90% of isolates, which 
ranged from 90.9% to 95.6%, were resistant to at least one CLSI subclass.   
 
In 2006, there were differences in resistance to antimicrobial agents between Shigella sonnei and Shigella flexneri 
(Tables 3.03 and 3.04).  Shigella sonnei isolates showed a higher prevalence of resistance to streptomycin than 
Shigella flexneri: 61.7% streptomycin resistance in S. sonnei, compared with 58.1% in S. flexneri.  However, S. 
flexneri showed a higher prevalence of resistance to tetracycline, sulfisoxazole, ampicillin, trimethoprim-
sulfamethoxazole, and chloramphenicol than S. sonnei:  83.8% tetracycline resistance in S. flexneri, compared 
with 22.7% in S. sonnei; 68.9% sulfisoxazole resistance in S. flexneri, compared with 33.3% in S. sonnei; and 
63.5% ampicillin resistance in S. flexneri, compared with 62.3% in S. sonnei. 
 
In all years from 1999 to 2006, resistance phenotypes ACSSuT and ACSuTm were higher in S. flexneri compared 
with S. sonnei (Tables 3.09 and 3.10).  The percentage of isolates with no detected resistance among S. sonnei 




Table 3.01: Frequency of Shigella species isolated in NARMS, 2006 
n (%)
Shigella sonnei 321 (79.9%)
Shigella flexneri 74 (18.4%)
Shigella boydii 4 (1.0%)







Table 3.02: Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2006 (N=402) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.9] 1.5 4.5 51.0 41.0 2.0
Gentamicin 0.0 0.2 [0.0–1.4] 3.7 39.1 55.5 1.5 0.2
Streptomycin NA 60.7 [55.7–65.5] 39.3 28.9 31.8
Aminopenicillins Ampicillin 1.0 62.2 [57.2–66.9] 7.7 23.6 4.2 1.2 1.0 0.5 61.7
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 16.7 1.5 [0.5–3.2] 3.2 6.7 27.9 44.0 16.7 1.5
Ceftiofur 0.0 0.2 [0.0–1.4] 22.4 67.7 9.0 0.7 0.2
Ceftriaxone 0.2 0.0 [0.0–0.9] 99.3 0.5 0.2
Ciprofloxacin 0.0 0.2 [0.0–1.4] 95.8 0.2 1.2 1.2 0.2 0.7 0.2 0.2
Nalidixic acid NA 3.5 [1.9–5.8] 4.7 70.9 18.4 2.2 0.2 1.2 2.2
Aminoglycosides Kanamycin 0.0 0.0 [0.0–0.9] 99.5 0.5
Cephamycins Cefoxitin 1.2 0.0 [0.0–0.9] 0.7 19.7 63.4 14.7 0.2 1.2
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 58.2 [53.2–63.1] 20.6 6.2 1.7 6.0 7.2 8.7 49.5
Phenicols Chloramphenicol 2.0 10.9 [8.1–14.4] 17.4 65.4 4.2 2.0 3.0 8.0
Sulfonamides Sulfisoxazole NA 40.3 [35.5–45.3] 48.8 8.5 2.0 0.5 40.3
Tetracyclines Tetracycline 0.2 34.6 [29.9–39.5] 65.2 0.2 1.2 7.7 25.6
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides
































Table 3.03: Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2006 (N=321) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.1] 1.6 4.4 59.2 32.7 2.2
Gentamicin 0.0 0.0 [0.0–1.1] 3.4 43.3 51.4 1.9
Streptomycin NA 61.7 [56.1–67.0] 38.3 34.0 27.7
Aminopenicillins Ampicillin 1.2 62.3 [56.8–67.6] 4.4 25.9 5.3 0.9 1.2 0.6 61.7
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 10.0 1.9 [0.7–4.0] 2.5 2.5 32.4 50.8 10.0 1.9
Ceftiofur 0.0 0.0 [0.0–1.1] 15.9 73.8 9.7 0.6
Ceftriaxone 0.0 0.0 [0.0–1.1] 99.4 0.6
Ciprofloxacin 0.0 0.0 [0.0–1.1] 96.6 0.3 0.9 1.6 0.3 0.3
Nalidixic acid NA 2.8 [1.3–5.3] 5.3 72.6 17.4 1.6 0.3 1.2 1.6
Aminoglycosides Kanamycin 0.0 0.0 [0.0–1.1] 99.7 0.3
Cephamycins Cefoxitin 1.6 0.0 [0.0–1.1] 0.6 23.4 65.7 8.4 0.3 1.6
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 57.9 [52.3–63.4] 19.9 4.0 1.9 7.2 9.0 10.9 47.0
Phenicols Chloramphenicol 2.2 0.9 [0.2–2.7] 11.8 80.1 5.0 2.2 0.3 0.6
Sulfonamides Sulfisoxazole NA 33.3 [28.2–38.8] 53.9 10.3 2.2 0.3 33.3
Tetracyclines Tetracycline 0.0 22.7 [18.3–27.7] 77.3 0.6 7.8 14.3
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides
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Table 3:04: Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2006 (N=74) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–4.9] 1.4 4.1 18.9 74.3 1.4
Gentamicin 0.0 1.4 [0.0–7.3] 4.1 24.3 70.3 1.4
Streptomycin NA 58.1 [46.1–69.5] 41.9 9.5 48.6
Aminopenicillins Ampicillin 0.0 63.5 [51.5–74.4] 21.6 12.2 2.7 63.5
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 44.6 0.0 [0.0–4.9] 4.1 25.7 8.1 17.6 44.6
Ceftiofur 0.0 1.4 [0.0–7.3] 47.3 44.6 5.4 1.4 1.4
Ceftriaxone 1.4 0.0 [0.0–4.9] 98.6 1.4
Ciprofloxacin 0.0 1.4 [0.0–7.3] 93.2 1.4 4.1 1.4
Nalidixic acid NA 5.4 [1.5–13.3] 2.7 64.9 23.0 4.1 5.4
Aminoglycosides Kanamycin 0.0 0.0 [0.0–4.9] 98.6 1.4
Cephamycins Cefoxitin 0.0 0.0 [0.0–4.9] 1.4 4.1 56.8 37.8
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 59.5 [47.4–70.7] 23.0 14.9 1.4 1.4 59.5
Phenicols Chloramphenicol 1.4 54.1 [42.1–65.7] 36.5 8.1 1.4 14.9 39.2
Sulfonamides Sulfisoxazole NA 68.9 [57.1–79.2] 28.4 1.4 1.4 68.9
Tetracyclines Tetracycline 1.4 83.8 [73.4–91.3] 14.9 1.4 4.1 6.8 73.0
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides





























Table 3.05: Percentage and number of Shigella isolates resistant to antimicrobial agents, 1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0
Gentamicin 0.3% 0.2% 0.0% 0.2% 0.0% 0.0% 1.0% 0.2%
(MIC ≥ 16) 1 1 0 1 0 0 4 1
Streptomycin 55.7% 57.1% 53.2% 54.4% 57.0% 61.0% 68.7% 60.7%
(MIC ≥ 64) 209 257 183 337 282 192 272 244
Ampicillin 77.6% 79.1% 79.7% 76.6% 79.4% 77.8% 70.7% 62.2%
(MIC ≥ 32) 291 356 274 475 393 245 280 250
Amoxicillin-clavulanic acid 1.1% 2.2% 4.4% 2.6% 1.4% 1.6% 1.0% 1.5%
(MIC ≥ 32) 4 10 15 16 7 5 4 6
Ceftiofur 0.0% 0.0% 0.0% 0.2% 0.2% 0.3% 0.5% 0.2%
(MIC ≥ 8) 0 0 0 1 1 1 2 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.0%
(MIC ≥ 64) 0 0 0 0 0 1 2 0
Ciprofloxacin 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.2%
(MIC ≥ 4) 0 0 1 0 0 0 0 1
Nalidixic acid 1.6% 0.9% 1.7% 1.6% 1.0% 1.6% 1.5% 3.5%
(MIC ≥ 32) 6 4 6 10 5 5 6 14
Aminoglycosides Kanamycin 0.5% 1.3% 0.6% 0.8% 0.4% 0.0% 0.8% 0.0%
(MIC ≥ 64) 2 6 2 5 2 0 3 0
Cephalothin 3.2% 8.0% 9.0% 6.6% 9.3% Not Not Not
(MIC ≥ 32) 12 36 31 41 46 Tested Tested Tested
Cefoxitin Not 0.2% 1.2% 0.3% 0.0% 0.3% 0.3% 0.0%
(MIC ≥ 32) Tested 1 4 2 0 1 1 0
Trimethoprim-sulfamethoxazole 51.5% 52.9% 46.8% 37.3% 38.6% 51.4% 58.6% 58.2%
(MIC ≥ 4) 193 238 161 231 191 162 232 234
Chloramphenicol 17.3% 14.0% 21.5% 7.6% 8.5% 14.9% 10.9% 10.9%
(MIC ≥ 32) 65 63 74 47 42 47 43 44
Sulfamethoxazole/Sulfisoxazole† 56.0% 55.8% 56.4% 31.8% 33.9% 52.4% 57.6% 40.3%
(MIC ≥ 512) 210 251 194 197 168 165 228 162
Tetracycline 57.3% 44.9% 59.3% 30.6% 29.1% 49.2% 38.4% 34.6%
(MIC ≥ 16) 215 202 204 190 144 155 152 139
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by 
















Table 3.06: Percentage and number of Shigella sonnei isolates resistant to antimicrobial agents, 1999–
2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0
Gentamicin 0.4% 0.3% 0.0% 0.0% 0.0% 0.0% 1.2% 0.0%
(MIC ≥ 16) 1 1 0 0 0 0 4 0
Streptomycin 52.0% 56.0% 54.0% 55.4% 56.5% 58.1% 70.3% 61.7%
(MIC ≥ 64) 143 205 129 297 245 140 239 198
Ampicillin 79.6% 80.6% 82.8% 77.6% 79.7% 79.3% 70.6% 62.3%
(MIC ≥ 32) 219 295 198 416 346 191 240 200
Amoxicillin-clavulanic acid 0.4% 1.9% 4.6% 2.2% 1.4% 1.7% 1.2% 1.9%
(MIC ≥ 32) 1 7 11 12 6 4 4 6
Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.0%
(MIC ≥ 8) 0 0 0 0 0 1 2 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.0%
(MIC ≥ 64) 0 0 0 0 0 1 2 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0
Nalidixic acid 1.5% 1.1% 0.8% 1.5% 0.5% 1.7% 1.2% 2.8%
(MIC ≥ 32) 4 4 2 8 2 4 4 9
Aminoglycosides Kanamycin 0.7% 1.6% 0.4% 0.4% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 2 6 1 2 0 0 0 0
Cephalothin 2.9% 8.7% 12.6% 7.3% 10.1% Not Not Not
(MIC ≥ 32) 8 32 30 39 44 Tested Tested Tested
Cefoxitin Not 0.3% 1.7% 0.4% 0.0% 0.4% 0.3% 0.0%
(MIC ≥ 32) Tested 1 4 2 0 1 1 0
Trimethoprim-sulfamethoxazole 53.1% 54.9% 50.6% 37.9% 38.5% 53.1% 61.2% 57.9%
(MIC ≥ 4) 146 201 121 203 167 128 208 186
Chloramphenicol 1.8% 2.7% 1.3% 0.2% 1.2% 2.5% 2.4% 0.9%
(MIC ≥ 32) 5 10 3 1 5 6 8 3
Sulfamethoxazole/Sulfisoxazole† 54.5% 56.0% 54.4% 29.9% 31.3% 49.0% 57.9% 33.3%
(MIC ≥ 512) 150 205 130 160 136 118 197 107
Tetracycline 46.2% 34.4% 44.8% 23.5% 22.1% 36.1% 29.4% 22.7%
(MIC ≥ 16) 127 126 107 126 96 87 100 73
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by 

















Table 3.07: Percentage and number of Shigella flexneri isolates resistant to antimicrobial agents,  
1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0% 1.4%
(MIC ≥ 16) 0 0 0 1 0 0 0 1
Streptomycin 63.2% 61.3% 47.3% 43.8% 60.8% 72.1% 57.7% 58.1%
(MIC ≥ 64) 55 46 43 32 31 44 30 43
Ampicillin 77.0% 77.3% 72.5% 75.3% 84.3% 82.0% 75.0% 63.5%
(MIC ≥ 32) 67 58 66 55 43 50 39 47
Amoxicillin-clavulanic acid 3.4% 4.0% 4.4% 5.5% 2.0% 1.6% 0.0% 0.0%
(MIC ≥ 32) 3 3 4 4 1 1 0 0
Ceftiofur 0.0% 0.0% 0.0% 1.4% 2.0% 0.0% 0.0% 1.4%
(MIC ≥ 8) 0 0 0 1 1 0 0 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0% 1.4%
(MIC ≥ 4) 0 0 1 0 0 0 0 1
Nalidixic acid 1.1% 0.0% 3.3% 2.7% 5.9% 1.6% 3.8% 5.4%
(MIC ≥ 32) 1 0 3 2 3 1 2 4
Aminoglycosides Kanamycin 0.0% 0.0% 1.1% 4.1% 3.9% 0.0% 3.8% 0.0%
(MIC ≥ 64) 0 0 1 3 2 0 2 0
Cephalothin 4.6% 2.7% 1.1% 2.7% 3.9% Not Not Not
(MIC ≥ 32) 4 2 1 2 2 Tested Tested Tested
Cefoxitin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested 0 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 48.3% 42.7% 34.1% 28.8% 39.2% 45.9% 44.2% 59.5%
(MIC ≥ 4) 42 32 31 21 20 28 23 44
Chloramphenicol 64.4% 69.3% 74.7% 63.0% 68.6% 60.7% 65.4% 54.1%
(MIC ≥ 32) 56 52 68 46 35 37 34 40
Sulfamethoxazole/Sulfisoxazole† 58.6% 53.3% 57.1% 41.1% 52.9% 65.6% 55.8% 68.9%
(MIC ≥ 512) 51 40 52 30 27 40 29 51
Tetracycline 92.0% 92.0% 94.5% 78.1% 82.4% 95.1% 94.2% 83.8%
(MIC ≥ 16) 80 69 86 57 42 58 49 62
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by 
















Table 3.08: Resistance patterns of Shigella isolates, 1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 375 450 344 620 495 315 396 402
% % % % % % % %
n n n n n n n n
No resistance detected 9.1% 7.3% 4.9% 8.2% 8.5% 4.4% 4.5% 5.2%
 34 33 17 51 42 14 18 21
Resistance ≥ 1 CLSI subclass* 90.9% 92.7% 95.1% 91.8% 91.5% 95.6% 95.5% 94.8%
 341 417 327 569 453 301 378 381
Resistance ≥ 2 CLSI subclasses* 63.7% 64.7% 69.8% 55.3% 57.8% 66.7% 73.7% 71.4%
 239 291 240 343 286 210 292 287
Resistance ≥ 3 CLSI subclasses* 61.1% 62.0% 61.3% 41.8% 41.4% 62.2% 62.9% 51.0%
 229 279 211 259 205 196 249 205
Resistance ≥ 4 CLSI subclasses* 54.1% 56.7% 54.1% 31.0% 32.5% 52.1% 55.6% 35.8%
 203 255 186 192 161 164 220 144
Resistance ≥ 5 CLSI subclasses* 40.5% 26.2% 36.0% 20.5% 22.4% 27.6% 15.7% 13.7%
 152 118 124 127 111 87 62 55
At least ACSSuT† 8.5% 5.6% 6.4% 1.8% 3.2% 6.0% 4.0% 5.0%
 32 25 22 11 16 19 16 20
At least ACSuTm‡ 9.9% 6.9% 7.0% 2.7% 3.6% 6.7% 6.3% 6.0%
 37 31 24 17 18 21 25 24
At least ASuTm§ 44.3% 44.4% 37.5% 29.8% 33.7% 37.8% 39.9% 34.1%
 166 200 129 185 167 119 158 137
At least ANSuTm¶ 0.3% 0.0% 0.6% 0.3% 0.8% 0.6% 0.5% 0.5%
 1 0 2 2 4 2 2 2
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
Resistance to quinolone‡‡ and cephalosporin§§ 0.0% 0.0% 0.0% 0.0% 0.2% 0.3% 0.3% 0.2%
 0 0 0 0 1 1 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  
‡‡Resistance to nalidixic acid (MIC ≥ 32) or decreased susceptibility to ciprofloxacin (MIC ≥ 0.12)
§§Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)  
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Table 3.09: Resistance patterns of Shigella sonnei isolates, 1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 275 366 239 536 434 241 340 321
% % % % % % % %
n n n n n n n n
No resistance detected 10.5% 7.7% 5.4% 7.1% 8.5% 5.0% 4.4% 4.7%
 29 28 13 38 37 12 15 15
Resistance ≥ 1 CLSI subclass* 89.5% 92.3% 94.6% 92.9% 91.5% 95.0% 95.6% 95.3%
 246 338 226 498 397 229 325 306
Resistance ≥ 2 CLSI subclasses* 56.0% 60.7% 60.7% 52.1% 54.1% 59.8% 72.6% 67.9%
 154 222 145 279 235 144 247 218
Resistance ≥ 3 CLSI subclasses* 54.5% 57.7% 53.1% 36.6% 36.2% 54.4% 60.0% 43.6%
 150 211 127 196 157 131 204 140
Resistance ≥ 4 CLSI subclasses* 50.5% 54.1% 49.0% 26.7% 28.6% 46.5% 53.5% 29.3%
 139 198 117 143 124 112 182 94
Resistance ≥ 5 CLSI subclasses* 38.5% 23.5% 36.0% 19.4% 20.0% 24.9% 11.5% 7.5%
 106 86 86 104 87 60 39 24
At least ACSSuT† 0.4% 0.8% 0.0% 0.0% 0.2% 0.0% 0.3% 0.0%
 1 3 0 0 1 0 1 0
At least ACSuTm‡ 1.8% 1.9% 0.8% 0.2% 0.9% 1.7% 2.4% 0.9%
 5 7 2 1 4 4 8 3
At least ASuTm§ 45.1% 46.2% 41.0% 30.2% 33.6% 39.4% 40.6% 32.1%
 124 169 98 162 146 95 138 103
At least ANSuTm¶ 0.0% 0.0% 0.0% 0.2% 0.2% 0.8% 0.3% 0.0%
 0 0 0 1 1 2 1 0
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.3% 0.0%
 0 0 0 0 0 1 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  
‡‡Resistance to nalidixic acid (MIC ≥ 32) or decreased susceptibility to ciprofloxacin (MIC ≥ 0.12)
§§Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)  
 
 
Table 3.10: Resistance patterns of Shigella flexneri isolates, 1999–2006 
Year 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 87 75 91 73 51 61 52 74
% % % % % % % %
n n n n n n n n
No resistance detected 4.6% 4.0% 3.3% 15.1% 7.8% 0.0% 5.8% 5.4%
 4 3 3 11 4 0 3 4
Resistance ≥ 1 CLSI subclass* 95.4% 96.0% 96.7% 84.9% 92.2% 100.0% 94.2% 94.6%
 83 72 88 62 47 61 49 70
Resistance ≥ 2 CLSI subclasses* 83.9% 82.7% 90.1% 76.7% 86.3% 93.4% 80.8% 86.5%
 73 62 82 56 44 57 42 64
Resistance ≥ 3 CLSI subclasses* 80.5% 81.3% 80.2% 75.3% 82.4% 91.8% 80.8% 81.1%
 70 61 73 55 42 56 42 60
Resistance ≥ 4 CLSI subclasses* 67.8% 69.3% 65.9% 58.9% 64.7% 75.4% 69.2% 62.2%
 59 52 60 43 33 46 36 46
Resistance ≥ 5 CLSI subclasses* 49.4% 40.0% 31.9% 28.8% 45.1% 41.0% 44.2% 40.5%
 43 30 29 21 23 25 23 30
At least ACSSuT† 33.3% 29.3% 22.0% 15.1% 29.4% 27.9% 28.8% 27.0%
 29 22 20 11 15 17 15 20
At least ACSuTm‡ 34.5% 32.0% 23.1% 21.9% 27.5% 24.6% 32.7% 28.4%
 30 24 21 16 14 15 17 21
At least ASuTm§ 44.8% 38.7% 25.3% 27.4% 37.3% 36.1% 38.5% 43.2%
 39 29 23 20 19 22 20 32
At least ANSuTm¶ 1.1% 0.0% 1.1% 1.4% 5.9% 0.0% 1.9% 2.7%
 1 0 1 1 3 0 1 2
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 2.0% 0.0% 0.0% 1.4%
 0 0 0 0 1 0 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  
‡‡Resistance to nalidixic acid (MIC ≥ 32) or decreased susceptibility to ciprofloxacin (MIC ≥ 0.12)
§§Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)  
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4. Escherichia coli O157 
 
From 1996 to 2006, there was no temporal trend in the percentage of isolates with resistance.  Among E. coli 
O157 isolates, resistance to antimicrobial agents was not common and multidrug resistance was rare. 
 
In 2006, CDC received a total of 251 Escherichia coli O157 isolates, of which 233 (92.8%) were viable non-
duplicates tested for antimicrobial susceptibility (Table II). Resistance to antimicrobial agents was not common.  
Antimicrobial agents with the highest prevalence of resistance were tetracycline (4.7%), sulfisoxazole (3.0%), 
ampicillin (2.6%), and streptomycin (2.6%). Three isolates in 2006 were resistant to ceftiofur, whereas no isolates 
were resistant in 2005 (Table 4.02). 
 
Isolates resistant to at least one CLSI subclass decreased from 12.4% in 2005 to 8.2% in 2006 (Table 4.03). Just 
as in 2004 and 2005, there were no isolates resistant to at least five subclasses in 2006.  From 1996 to 2006, 
there was no temporal trend in the percentage of isolates with no detected resistance, which ranged from 86.6% 
to 95.3% during the 11-year surveillance period.   
Table 4.01: Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2006 (N=233) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.6] 6.0 66.1 21.9 5.2 0.9
Gentamicin 0.0 0.0 [0.0–1.6] 51.9 42.1 5.6 0.4
Streptomycin NA 2.6 [1.0–5.5] 97.4 1.3 1.3
Aminopenicillins Ampicillin 0.4 2.6 [1.0–5.5] 4.3 78.5 12.9 1.3 0.4 2.6
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.4 1.3 [0.3–3.7] 1.7 9.0 86.3 1.3 0.4 0.4 0.9
Ceftiofur 0.0 1.3 [0.3–3.7] 1.7 24.5 69.5 3.0 1.3
Ceftriaxone 0.4 0.9 [0.1–3.1] 97.9 0.9 0.4 0.9
Ciprofloxacin 0.0 0.4 [0.0–2.4] 97.0 0.4 1.3 0.9 0.4
Nalidixic acid NA 2.1 [0.7–4.9] 0.4 2.1 87.1 7.3 0.4 0.4 0.4 1.7
Aminoglycosides Kanamycin 0.0 0.4 [0.0–2.4] 99.1 0.4 0.4
Cephamycins Cefoxitin 0.9 1.3 [0.3–3.7] 2.1 7.3 78.1 10.3 0.9 0.4 0.9
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.4 [0.0–2.4] 94.4 5.2 0.4
Phenicols Chloramphenicol 0.9 1.3 [0.3–3.7] 1.3 27.0 69.5 0.9 1.3
Sulfonamides Sulfisoxazole NA 3.0 [1.2–6.1] 81.1 14.6 1.3 3.0
Tetracyclines Tetracycline 0.0 4.7 [2.4–8.3] 95.3 0.4 1.3 3.0
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the 
precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides




























Table 4.02: Percentage and number of Escherichia coli O157 isolates resistant to antimicrobial agents, 
1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Aminoglycosides Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.3% 0.5% 0.4% 0.0% 0.0% 0.6% 0.5% 0.0%
(MIC ≥ 16) 0 0 0 1 2 1 0 0 1 1 0
Streptomycin 2.0% 2.5% 1.9% 2.7% 5.2% 1.8% 2.3% 1.9% 1.8% 2.1% 2.6%
(MIC ≥ 64) 4 4 6 8 21 5 9 3 3 4 6
Aminopenicillins Ampicillin 1.5% 0.0% 2.5% 1.4% 2.7% 2.2% 1.5% 3.2% 1.2% 4.1% 2.6%
(MIC ≥ 32) 3 0 8 4 11 6 6 5 2 8 6
Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.3% 1.0% 0.7% 0.0% 1.3% 0.0% 0.0% 1.3%
(MIC ≥ 32) 0 0 0 1 4 2 0 2 0 0 3
Ceftiofur 0.0% 0.0% 0.0% 0.0% 1.0% 1.1% 0.0% 1.3% 0.0% 0.0% 1.3%
(MIC ≥ 8) 0 0 0 0 4 3 0 2 0 0 3
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0 2
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0 1
Nalidixic acid 0.0% 0.0% 0.0% 0.7% 0.5% 1.1% 1.0% 0.6% 1.8% 1.5% 2.1%
(MIC ≥ 32) 0 0 0 2 2 3 4 1 3 3 5
Aminoglycosides Kanamycin 0.0% 0.0% 0.3% 0.7% 1.0% 0.0% 0.5% 0.0% 0.0% 0.5% 0.4%
(MIC ≥ 64) 0 0 1 2 4 0 2 0 0 1 1
Cephalothin 1.5% 2.5% 0.0% 0.7% 1.2% 1.4% 1.5% 2.5% Not Not Not
(MIC ≥ 32) 3 4 0 2 5 4 6 4 Tested Tested Tested
Cephamycins Cefoxitin Not Not Not Not 1.0% 0.7% 0.0% 1.3% 0.6% 0.0% 1.3%
(MIC ≥ 32) Tested Tested Tested Tested 4 2 0 2 1 0 3
Folate pathway inhibitors Trimethoprim-sulfamethoxazole 0.0% 0.0% 0.6% 1.4% 0.7% 0.7% 0.5% 0.6% 0.0% 0.5% 0.4%
(MIC ≥ 4) 0 0 2 4 3 2 2 1 0 1 1
Phenicols Chloramphenicol 0.5% 0.0% 0.3% 0.0% 3.7% 1.4% 1.3% 1.3% 0.6% 1.0% 1.3%
(MIC ≥ 32) 1 0 1 0 15 4 5 2 1 2 3
Sulfonamides Sulfamethoxazole/Sulfisoxazole† 11.9% 9.9% 5.7% 8.2% 5.9% 5.1% 3.5% 3.8% 1.8% 6.7% 3.0%
(MIC ≥ 512) 24 16 18 24 24 14 14 6 3 13 7
Tetracyclines Tetracycline 5.0% 3.1% 4.4% 3.4% 7.1% 5.4% 3.0% 5.7% 1.8% 8.8% 4.7%
(MIC ≥ 16) 10 5 14 10 29 15 12 9 3 17 11
†Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole 
therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 









Table 4.03: Resistance patterns of Escherichia coli O157 isolates, 1996–2006 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 201 161 318 292 407 277 399 157 169 194 233
% % % % % % % % % % %
n n n n n n n n n n n
No resistance detected 86.6% 88.8% 92.8% 89.7% 90.4% 91.3% 94.0% 90.4% 95.3% 87.6% 91.8%
 174 143 295 262 368 253 375 142 161 170 214
Resistance ≥ 1 CLSI subclass* 13.4% 11.2% 7.2% 10.3% 9.6% 8.7% 6.0% 9.6% 4.7% 12.4% 8.2%
 27 18 23 30 39 24 24 15 8 24 19
Resistance ≥ 2 CLSI subclasses* 5.0% 3.7% 5.3% 3.4% 6.6% 5.4% 3.8% 5.1% 1.2% 5.2% 3.4%
 10 6 17 10 27 15 15 8 2 10 8
Resistance ≥ 3 CLSI subclasses* 1.5% 0.6% 1.9% 3.1% 4.7% 2.2% 2.0% 3.2% 0.6% 1.0% 3.0%
 3 1 6 9 19 6 8 5 1 2 7
Resistance ≥ 4 CLSI subclasses* 0.5% 0.0% 0.9% 1.0% 3.7% 1.8% 1.0% 1.3% 0.6% 0.5% 1.7%
 1 0 3 3 15 5 4 2 1 1 4
Resistance ≥ 5 CLSI subclasses* 0.5% 0.0% 0.0% 0.7% 1.5% 0.7% 0.3% 0.6% 0.0% 0.0% 0.0%
 1 0 0 2 6 2 1 1 0 0 0
At least ACSSuT† 0.5% 0.0% 0.0% 0.0% 1.2% 0.4% 0.0% 0.0% 0.0% 0.0% 0.9%
 1 0 0 0 5 1 0 0 0 0 2
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 0 0 0 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0 0 0
Resistance to quinolone** and cephalosporin†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.3%
 0 0 0 0 0 0 0 0 0 0 3
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
††Decreased susceptibility to ceftiofur (MIC ≥ 2) or ceftriaxone (MIC ≥ 2)







Among all Campylobacter isolates tested, ciprofloxacin resistance increased from 12.9% in 1997 to 21.7 in 2005 
and decreased to 19.6% in 2006.  Resistance to erythromycin remained low during the period from 1997 to 2006. 
A decrease in ciprofloxacin resistance in C. jejuni was observed similar to the trend in all Campylobacter. The 
percentage of resistance to most antimicrobial agents tested, including ciprofloxacin and erythromycin, was higher 
in C. coli compared with C. jejuni.  
 
In 2006, CDC received 920 Campylobacter isolates, of which 816 (88.7%) were viable non-duplicates tested for 
antimicrobial susceptibility. A total of 709 (86.9%) were C. jejuni, 97 (11.9%) were C. coli, and 10 (1.2%) were 
other species (Table 5.01). 
 
Of the Campylobacter isolates tested in 2006 (Table II), resistance was highest to tetracycline (46.0%), nalidixic 
acid (20.1%), and ciprofloxacin (19.6%) (Table 5.02). Of the isolates tested, none were resistant to florfenicol, 
which replaced chloramphenicol to represent the phenicol antimicrobial subclass. 
 
The percentage of Campylobacter isolates resistant to ciprofloxacin significantly increased from 12.9% in 1997 to 
19.6% in 2006 (OR=2.0, 95% CI [1.3, 3.1]).  Resistance to erythromycin remained low at 2.1% or less from 1997 
to 2006.  It increased from 0.3% in 2004 to 1.7% in 2006 (Table 5.03). 
 
In 2006, 56.1% of Campylobacter isolates were resistant to one or more CLSI subclass, compared with 51.6% in 
2005 (Table 5.04). In 2006, 12.0% of Campylobacter isolates were resistant to two or more subclasses, compared 
with 13.6% in 2005. 
 
The antimicrobial agent with the highest prevalence of resistance among the 709 C. jejuni isolates was tetracycline 
(47.4%), followed by ciprofloxacin (19.5%), and nalidixic acid (19.0%) (Table 5.05). Of note, 0.0% and 0.8% of C. 
jejuni isolates were resistant to gentamicin and erythromycin, respectively. 
 
The percentage of C. jejuni isolates resistant to ciprofloxacin increased from 12.4% in 1997 to 19.5% in 2006 
(Table 5.06); this increase was statistically significant (OR=2.0, 95% CI [1.3, 3.3]).  Erythromycin resistance was 
low at 1.9% or less from 1997 to 2006. 
 
The percentage of resistance to most agents tested, including ciprofloxacin and erythromycin, was higher in C. 
coli compared with C. jejuni.  In 2006, the highest levels of resistance among the 97 C. coli isolates were to 
tetracycline (39.2%), nalidixic acid (23.7%), and ciprofloxacin (21.6%) (Table 5.07). The percentage of C. coli 
isolates resistant to ciprofloxacin was 33.3% in 1997, not detected in 1998, but ranged from 12.0% to 47.1% from 
1999 to 2006; it was 21.6% in 2006 (Table 5.08). Resistance to erythromycin was not detected in 1997, 12.5% in 
1998, ranged from 4.0% to 10.0% during 1999 to 2003, decreased to 0.0% in 2004, and increased to 8.2% in 
2006. 
 
Table 5.01: Frequency of Campylobacter species isolated in NARMS, 2006 
 
n (%)
Campylobacter jejuni 709 (86.9%)







Table 5.02: Minimum inhibition concentrations (MICs) and resistance of Campylobacter isolates to 
antimicrobial agents, 2006 (N=816) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   0.1 [0.0–0.7] 7.6 33.5 51.7 6.7 0.4 0.1
Ketolide Telithromycin   0.5   1.6 [0.9–2.7] 0.2 1.6 12.6 30.0 30.4 19.2 3.8 0.5 1.6
Azithromycin   0.0   1.7 [0.9–2.9] 3.6 25.4 34.3 25.1 8.8 0.9 0.2 1.7
Erythromycin   0.0   1.7 [0.9–2.9] 0.9 7.2 27.7 33.6 22.2 4.8 2.0 0.1 1.6
Ciprofloxacin   0.1  19.6 [16.9–22.5] 0.2 5.3 36.2 29.0 8.3 1.2 0.1 2.0 8.3 5.9 2.0 1.2 0.2
Nalidixic acid   0.4  20.1 [17.4–23.0] 58.3 18.1 3.1 0.4 2.6 17.5
Phenicols Florfenicol** N/A   0.0 [0.0–0.5] 2.0 18.4 60.8 16.3 2.6
Tetracyclines Tetracycline   0.5  46.0 [42.5–49.4] 6.0 22.4 17.0 4.5 2.7 0.7 0.1 0.5 1.5 3.2 12.3 29.0
III Lincosamides Clindamycin   0.1   2.0 [1.1–3.2] 3.9 21.7 39.8 22.1 7.5 2.0 1.0 0.1 0.2 0.7 1.0
†Percent of isolates with intermediate susceptibility
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints




¶The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire 




























Table 5.03: Percentage and number of Campylobacter isolates resistant to antimicrobial agents, 1997–2006 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.7% 0.1%
(MIC ≥ 8) Tested 1 0 1 0 0 1 1 6 1
Ketolides Telithromycin Not Not Not Not Not Not Not Not 1.0% 1.6%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 9 13
Macrolides Azithromycin Not 0.6% 2.2% 1.9% 2.1% 2.0% 0.9% 0.6% 1.9% 1.7%
(MIC ≥ 8) Tested 2 7 6 8 7 3 2 17 14
Erythromycin 1.8% 1.0% 1.9% 1.2% 2.1% 1.4% 0.9% 0.3% 1.8% 1.7%
(MIC ≥ 32) 4 3 6 4 8 5 3 1 16 14
Quinolones Ciprofloxacin 12.9% 13.9% 18.3% 14.8% 19.5% 20.1% 17.7% 19.0% 21.7% 19.6%
(MIC ≥ 4) 28 43 58 48 75 71 58 66 193 160
Nalidixic acid 14.3% 16.8% 21.1% 16.7% 20.3% 20.6% 18.9% 19.6% 22.4% 20.1%
(MIC ≥ 64) 31 52 67 54 78 73 62 68 199 164
Phenicols Chloramphenicol 5.1% 2.9% 0.6% 0.0% 0.3% 0.3% 0.0% 1.4% Not Not
(MIC ≥ 32) 11 9 2 0 1 1 0 5 Tested Teste
Florfenicol
d
† Not Not Not Not Not Not Not Not 0.6% 0.0%
Susceptible breakpoint: (MIC < 4) Tested Tested Tested Tested Tested Tested Tested Tested 5 0
Tetracyclines Tetracycline 47.9% 45.5% 43.8% 38.3% 40.9% 41.2% 38.4% 46.1% 40.6% 46.0%
(MIC ≥ 16) 104 141 139 124 157 146 126 160 361 375
Lincosamides Clindamycin 1.8% 1.3% 1.3% 0.9% 2.1% 2.0% 0.6% 2.0% 1.5% 2.0%
(MIC ≥ 8) 4 4 4 3 8 7 2 7 13 16
† Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important 
(Rank I) as (1) sole therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases 
caused by organisms that may acquire resistance genes from non-human sources.  Antimicrobials are highly important (Rank II) if either criteria (1) or (2) are true.  Antimicrobial agents are considered 








Table 5.04: Resistance patterns of Campylobacter isolates, 1997–2006 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total Isolates 217 310 317 324 384 354 328 347 890 816
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 47.0% 45.2% 47.3% 52.2% 49.2% 48.3% 50.9% 46.1% 48.4% 43.9%
 102 140 150 169 189 171 167 160 431 358
Resistance ≥ 1 CLSI subclass* 53.0% 54.8% 52.7% 47.8% 50.8% 51.7% 49.1% 53.9% 51.6% 56.1%
 115 170 167 155 195 183 161 187 459 458
Resistance ≥ 2 CLSI subclasses* 15.7% 9.7% 13.6% 8.0% 13.3% 12.7% 8.5% 14.1% 13.6% 12.0%
 34 30 43 26 51 45 28 49 121 98
Resistance ≥ 3 CLSI subclasses* 1.8% 2.6% 1.6% 0.9% 1.6% 1.1% 0.9% 1.2% 1.5% 1.5%
 4 8 5 3 6 4 3 4 13 12
Resistance ≥ 4 CLSI subclasses* 0.5% 0.3% 0.9% 0.3% 0.3% 0.0% 0.3% 0.3% 0.3% 0.5%
 1 1 3 1 1 0 1 1 3 4
Resistance ≥ 5 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute  
 
Table 5.05: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2006, (N=709) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   0.0 [0.0–0.5] 8.5 37.5 49.6 4.1 0.3
Ketolide Telithromycin   0.1   0.8 [0.3–1.8] 0.3 1.7 12.4 31.5 32.6 19.0 1.6 0.1 0.8
Azithromycin   0.0   0.8 [0.3–1.8] 4.1 28.1 37.7 22.8 6.1 0.3 0.1 0.8
Erythromycin   0.0   0.8 [0.3–1.8] 1.0 8.2 30.9 34.3 20.6 3.5 0.7 0.8
Ciprofloxacin   0.1  19.5 [16.6–22.6] 0.3 5.9 39.5 28.2 5.8 0.7 0.1 1.8 8.3 5.8 2.1 1.1 0.3
Nalidixic acid   0.4  19.0 [16.2–22.1] 62.3 15.8 2.4 0.4 2.3 16.8
Phenicols Florfenicol** N/A   0.0 [0.0–0.5] 2.3 20.2 61.6 13.7 2.3
Tetracyclines Tetracycline   0.6  47.4 [43.7–51.1] 6.6 24.3 15.2 3.2 2.0 0.6 0.1 0.6 1.6 3.7 13.8 28.3
III Lincosamides Clindamycin   0.0   1.0 [0.4–2.0] 4.4 24.4 43.6 20.0 5.2 0.8 0.6 0.1 0.4 0.4
†Percent of isolates with intermediate susceptibility
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
¶The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  


























Table 5.06: Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 
1997–2006 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.0%
(MIC ≥ 8) Tested 1 0 0 0 0 0 1 4 0
Ketolides Telithromycin Not Not Not Not Not Not Not Not 0.0% 0.8%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 0 6
Macrolides Azithromycin Not 0.3% 1.7% 1.6% 1.9% 1.8% 0.3% 0.6% 1.8% 0.8%
(MIC ≥ 8) Tested 1 5 5 7 6 1 2 14 6
Erythromycin 1.4% 0.7% 1.4% 1.0% 1.9% 1.2% 0.3% 0.3% 1.6% 0.8%
(MIC ≥ 32) 3 2 4 3 7 4 1 1 13 6
Quinolones Ciprofloxacin 12.4% 13.8% 17.7% 14.7% 18.4% 20.7% 17.2% 18.1% 21.5% 19.5%
(MIC ≥ 4) 26 41 52 45 67 68 52 58 170 138
Nalidixic acid 13.4% 15.5% 20.1% 16.0% 18.9% 21.3% 17.8% 18.4% 21.9% 19.0%
(MIC ≥ 64) 28 46 59 49 69 70 54 59 173 135
Phenicols Chloramphenicol 3.8% 1.0% 0.7% 0.0% 0.3% 0.3% 0.0% 1.6% Not Not
(MIC ≥ 32) 8 3 2 0 1 1 0 5 Tested Teste
Florfenicol* Not Not Not Not Not Not Not Not 0.5% 0.0%
Susceptible breakpoint: (MIC < 4) Tested Tested Tested Tested Tested Tested Tested Tested 4 0
Tetracyclines Tetracycline 47.8% 46.1% 45.4% 39.2% 40.3% 41.3% 38.3% 46.9% 41.8% 47.4%
(MIC ≥ 16) 100 137 133 120 147 136 116 150 331 336
Lincosamides Clindamycin 1.0% 1.0% 0.7% 0.7% 1.9% 1.8% 0.0% 2.2% 1.1% 1.0%
(MIC ≥ 8) 2 3 2 2 7 6 0 7 9 7
† Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important 
(Rank I) as (1) sole therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases 
caused by organisms that may acquire resistance genes from non-human sources.  Antimicrobials are highly important (Rank II) if either criteria (1) or (2) are true.  Antimicrobial agents are considered 







Table 5.07: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2006 (N=97) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   1.0 [0.0–5.6] 2.1 6.2 63.9 25.8 1.0 1.0
Ketolide Telithromycin   2.1   7.2 [3.0–14.3] 1.0 14.4 21.6 14.4 20.6 18.6 2.1 7.2
Azithromycin   0.0   8.2 [3.6–15.6] 8.2 11.3 41.2 24.7 5.2 1.0 8.2
Erythromycin   0.0   8.2 [3.6–15.6] 1.0 6.2 29.9 29.9 13.4 11.3 1.0 7.2
Ciprofloxacin   0.0  21.6 [13.9–31.2] 1.0 15.5 35.1 22.7 4.1 3.1 9.3 7.2 1.0 1.0
Nalidixic acid   0.0  23.7 [15.7–33.4] 32.0 36.1 8.2 5.2 18.6
Phenicols Florfenicol** N/A   0.0 [0.0–3.7] 7.2 54.6 33.0 5.2
Tetracyclines Tetracycline   0.0  39.2 [29.4–49.6] 2.1 9.3 29.9 12.4 5.2 2.1 2.1 37.1
III Lincosamides Clindamycin   1.0   9.3 [4.3–16.9] 1.0 3.1 15.5 36.1 22.7 7.2 4.1 1.0 1.0 3.1 5.2
†Percent of isolates with intermediate susceptibility
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints




*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 
¶The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  



























Table 5.08: Percentage and number of Campylobacter coli isolates resistant to antimicrobial agents, 1997–
2006 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006




Aminoglycosides Gentamicin Not 0.0% 0.0% 8.3% 0.0% 0.0% 4.5% 0.0% 2.0% 1.0%
(MIC ≥ 8) Tested 0 0 1 0 0 1 0 2 1
Ketolides Telithromycin Not Not Not Not Not Not Not Not 4.1% 7.2%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 4 7
Macrolides Azithromycin Not 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1% 8.2%
(MIC ≥ 8) Tested 1 2 1 1 1 2 0 3 8
Erythromycin 0.0% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1% 8.2%
(MIC ≥ 32) 0 1 2 1 1 1 2 0 3 8
Quinolones Ciprofloxacin 33.3% 0.0% 30.0% 25.0% 47.1% 12.0% 22.7% 30.8% 23.5% 21.6%
(MIC ≥ 4) 2 0 6 3 8 3 5 8 23 21
Nalidixic acid 50.0% 50.0% 30.0% 25.0% 47.1% 12.0% 22.7% 34.6% 26.5% 23.7%
(MIC ≥ 64) 3 4 6 3 8 3 5 9 26 23
Phenicols Chloramphenicol 50.0% 37.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Not Not
(MIC ≥ 32) 3 3 0 0 0 0 0 0 Tested Teste
Florfenicol* Not Not Not Not Not Not Not Not 1.0% 0.0%
Susceptible breakpoint: (MIC < 4) Tested Tested Tested Tested Tested Tested Tested Tested 1 0
Tetracyclines Tetracycline 66.7% 50.0% 30.0% 25.0% 58.8% 40.0% 45.5% 38.5% 30.6% 39.2%
(MIC ≥ 16) 4 4 6 3 10 10 10 10 30 38
Lincosamides Clindamycin 16.7% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 4.1% 9.3%
(MIC ≥ 8) 1 1 2 1 1 1 2 0 4 9
† Only a susceptible breakpoint (≤ 4 μg/ml) has been established. In this report, isolates with an MIC ≥ 8 μg/ml are categorized as resistant
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important 
(Rank I) as (1) sole therapies or one of the few alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via non-human sources or diseases 
caused by organisms that may acquire resistance genes from non-human sources.  Antimicrobials are highly important (Rank II) if either criteria (1) or (2) are true.  Antimicrobial agents are considered 








Limitations to NARMS Campylobacter Surveillance 
 
Three limitations are evident in NARMS Campylobacter surveillance: (1) the use of sentinel clinical laboratories in 
FoodNet states, (2) the sampling scheme implemented during 1997 to 2004, and (3) the limited geographic area 
under surveillance. 
 
Four of the states that participated in NARMS Campylobacter surveillance during 1997 to 2004, (California, 
Colorado, Connecticut, and Oregon), submitted Campylobacter isolates to NARMS from one sentinel clinical 
laboratory within their state. The other six states (Georgia, Maryland, Minnesota, New Mexico, New York, and 
Tennessee), submitted Campylobacter isolates that were selected from most clinical laboratories within a specific 
geographic area (metro Atlanta area in Georgia; statewide in Maryland, Minnesota, New Mexico, and Tennessee; 
and the metro Albany and Rochester areas in New York). In California, Colorado, Connecticut, and Oregon, the 
sentinel clinical laboratory selected the first Campylobacter isolate isolated each week for submission to NARMS; 
if no isolate was isolated in a week, then no isolate was submitted from that laboratory. From the other six 
FoodNet sites, one Campylobacter isolate among isolates received from participating clinical laboratories was 
also selected each week.  Because none of the sentinel clinical laboratories used an isolation procedure that was 
more or less likely than the procedure of other clinical laboratories in their respective states to yield antimicrobial-
resistant Campylobacter isolates, use of a sentinel clinical laboratory was unlikely to be associated with a change 
of antimicrobial resistance among Campylobacter isolates submitted to NARMS. 
 
From 1997 to 2004, the participating public health laboratories in Georgia, Maryland, Minnesota, New Mexico, 
New York, and Tennessee, and sentinel clinical laboratories in all other FoodNet sites selected one 
Campylobacter isolate each week and forwarded the isolate to CDC. When the isolates were selected, the 
antimicrobial resistance pattern of the isolates was not known. Therefore, the antimicrobial resistance pattern of 
an isolate was unlikely to influence submission of the isolate to NARMS. However, the one-sample-a-week 
scheme could have resulted in oversampling or undersampling of antimicrobial-resistant isolates if the prevalence 
of such resistance was not uniform throughout the year. The impact of oversampling or undersampling can vary 
among states.  In 2005, a representative sampling scheme was initiated in the 10 FoodNet sites. 
 
Campylobacter isolates were forwarded to CDC by 10 states participating in FoodNet during 2006, representing 
approximately 45 million persons (15% of the U.S. population). Because NARMS 2006 Campylobacter surveillance 
was not nationwide, findings should be generalized to the U.S. population with caution because of possible 
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Escherichia coli is a Gram–negative coccobacillus bacterium that is part of the intestinal flora of humans and 
other animals. Because antimicrobial resistance genes commonly reside in mobile genetic elements that can be 
transferred horizontally to other bacteria, antimicrobial–resistant bacteria of the intestinal flora, including E. coli, 
constitute an important reservoir of resistance genes for pathogenic bacteria of humans and other animals. 
Furthermore, when introduced into a normally sterile site, E. coli is an important cause of infections, including 
septicemia, urinary tract infections, and wound infections. The human intestinal tract is the predominant source of 
E. coli causing these infections. Antimicrobial resistance among E. coli causing such infections complicates 
treatment options. 
 
The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant 
bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant E. coli in the 
intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply. 
Therefore, monitoring resistance in E. coli isolated from the intestinal flora of humans and animals is important to 
determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for 
human pathogens. The E. coli Resistance Surveillance Pilot is designed to determine the prevalence of 
resistance to clinically important antimicrobial agents among E. coli isolated from persons in the community. 
 




Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of E. coli 






SURVEILLANCE AND LABORATORY TESTING METHODS 
 
Participating laboratories in Maryland and Michigan cultured 10 human stool samples each month for E. coli using 
Eosin Methylene Blue agar. One E. coli isolate, if present, from each stool sample was sent to CDC for 
susceptibility testing to antimicrobial agents using broth microdilution (Sensititre®) to determine the minimum 
inhibitory concentration (MIC) for each of 15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfonamides, tetracycline, and trimethoprim-sulfamethoxazole (Table A.01).  
 
Interpretive criteria from CLSI were used (Table A.01). The 95% CIs for the percentage of resistant isolates 
calculated using the Clopper-Pearson exact method, are included in the MIC distribution tables. Similarly, 




In 2006, CDC received and tested 82 viable E. coli isolates (Table A.02). MIC was determined for E. coli isolates 
for 15 antimicrobial agents (Table A.03). 
 
Of the E. coli isolates, 28.0% were resistant to ampicillin; 17.1%, to sulfonamides; 14.6% to tetracycline; and 
11.0% to nalidixic acid (Table A.04). 
 
In 2006, 22.0% of E. coli isolates were resistant to two or more CLSI subclasses, and 1.2% were resistant to five 
or more CLSI subclasses (Table A.05). The level of E. coli resistance in this pilot study differs than that observed 
in NARMS 2005 routine E. coli O157. Because of the different sampling methods between this study and NARMS 
routine surveillance, this observation requires further investigation. 
 
There is a difference in the level of resistance among E. coli isolates in this study compared with E. coli O157 
isolates submitted to NARMS in 2006. Because of the different sampling methods employed between this study 
and NARMS, this observation requires further investigation. 
 
Multidrug-Resistant E. coli 
 
• 22.0% of 82 E. coli isolates tested were resistant to two or more subclasses of antimicrobial agents. 
• 1.2% of 82 E. coli isolates tested were resistant to five or more subclasses of antimicrobial agents. 
 
Clinically Important Resistance 
 
Antimicrobial agents commonly used to treat serious E. coli infections in humans include third-generation 
cephalosporins and fluoroquinolones. 
• 0.0% of 82 E. coli isolates were resistant to ceftiofur (Table A.04). 
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Table A.01: Antimicrobial agents used for susceptibility testing of Escherichia coli, 2006 
Susceptible Intermediate Resistant
Amikacin 0.5 – 64 ≤16 32 ≥64
Gentamicin 0.25 – 16 ≤4 8 ≥16
Kanamycin 8 – 64 ≤16 32 ≥64
Streptomycin 32 – 64 ≤32  ≥64
Aminopenicillins Ampicillin 1 – 32 ≤8 16 ≥32
β-lactamase inhibitor combinations Amoxicillin–Clavulanic acid 1/0.5 – 32/16 ≤8/4 16/8 ≥32/16
Ceftiofur 0.12– 8 ≤2 4 ≥8
Ceftriaxone 0.25 – 64 ≤8 16-32 ≥64
Cephamycins Cefoxitin 0.5 – 32 ≤8 16 ≥32
Folate pathway inhibitors Trimethoprim–Sulfamethoxazole 0.12/2.4 – 4/76 ≤2/38 ≥4/76
Phenicols Chloramphenicol 2 – 32 ≤8 16 ≥32
Ciprofloxacin 0.015 – 4 ≤1 2 ≥4
Nalidixic acid 0.5 – 32 ≤16 ≥32
Sulfonamides Sulfisoxazole 16 – 256 ≤256 ≥512
Tetracyclines Tetracycline 4 – 32 ≤4 8 ≥16









Table A.02: Escherichia coli isolates received and tested at CDC, by site, 2006 







Table A.03: Minimum inhibition concentrations (MICs) and resistance of Escherichia coli isolates to 
antimicrobial agents, 2006 (N=82) 
%I† %R‡ [95% CI]§ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–2.6] 2.4 42.7 52.4 1.2 1.2
Gentamicin 1.2 3.7 [2.2–8.3] 26.8 61.0 4.9 2.4 1.2 1.2 2.4
Streptomycin NA 7.3 [9.6–19.2] 92.7 3.7 3.7
Aminopenicillins Ampicillin 0.0 28.0 [24.1–36.7] 13.4 43.9 12.2 2.4 28.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 2.4 3.7 [1.6–7.2] 3.7 28.0 39.0 23.2 2.4 3.7
Ceftiofur 0.0 0.0 [0.0–2.6] 11.0 58.5 28.0 2.4
Ceftriaxone 0.0 0.0 [0.0–2.6] 100.0
Ciprofloxacin 0.0 4.9 [5.7–13.9] 85.4 2.4 4.9 1.2 1.2 4.9
Nalidixic Acid NA 11.0 [14.0–24.9] 19.5 63.4 3.7 1.2 1.2 1.2 9.8
Aminoglycosides Kanamycin 0.0 0.0 [0.8–5.3] 97.6 2.4
Cephamycins Cefoxitin 2.4 1.2 [1.3–6.6] 1.2 9.8 50.0 28.0 7.3 2.4 1.2
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 12.2 [11.2–21.3] 81.7 6.1 1.2 11.0
Phenicols Chloramphenicol 1.2 3.7 [0.5–4.7] 6.1 58.5 30.5 1.2 1.2 2.4
Sulfonamides Sulfisoxazole NA 17.1 [17.7–29.4] 56.1 25.6 1.2 17.1
Tetracyclines Tetracycline 0.0 14.6 [12.4–22.8] 85.4 1.2 13.4
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for resistance. 
Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the precentages 
of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)¶
Aminoglycosides







*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine (Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or 


































Table A.04: Percentage and number of Escherichia coli isolates resistant to antimicrobial agents, 2004–
2006 
Year 2004 2005 2006




Amikacin 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0
Gentamicin 2.0% 3.4% 3.7%
(MIC ≥ 16) 3 4 3
Streptomycin 10.6% 14.3% 7.3%
(MIC ≥ 64) 16 17 6
Ampicillin 24.5% 26.1% 28.0%
(MIC ≥ 32) 37 31 23
Amoxicillin-clavulanic acid 2.6% 4.2% 3.7%
(MIC ≥ 32) 4 5 3
Ceftiofur 0.0% 0.8% 0.0%
(MIC ≥ 8) 0 1 0
Ceftriaxone 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0
Ciprofloxacin 3.3% 7.6% 4.9%
(MIC ≥ 4) 5 9 4
Nalidixic Acid 9.3% 9.2% 11.0%
(MIC ≥ 32) 14 11 9
Aminoglycosides Kanamycin 2.0% 0.0% 0.0%
(MIC ≥ 64) 3 0 0
Cefoxitin 2.6% 0.8% 1.2%
(MIC ≥ 32) 4 1 1
Trimethoprim-sulfamethoxazole 11.3% 14.9% 12.2%
(MIC ≥ 4) 17 17 10
Chloramphenicol 1.3% 2.5% 3.7%
(MIC ≥ 32) 2 3 3
Sulfisoxazole 17.9% 18.4% 17.1%
(MIC ≥ 512) 27 21 14
Tetracycline 13.2% 19.3% 14.6%
(MIC ≥ 16) 20 23 12
†Five isolates do not have test results for Trimethoprim-sulfamethoxazole and Sulfamethoxazole/Sulfisoxazole.
*Rank of antimicrobials based on World Health Organization's categorization of critical importance in human medicine 
(Table I).  Antimicrobial agents are considered critically important (Rank I) as (1) sole therapies or one of the few 
alternatives to treat serious human diseases and (2) used to treat disease caused by organisms that may be transmitted via 
non-human sources or diseases caused by organisms that may acquire resistance genes from non-human sources.  

















Table A.05: Resistance patterns of Escherichia coli isolates, 2004–2006 
Year 2004 2005 2006
Total Isolates 151 119 82
% % %
n n n
No resistance detected 62.9% 63.0% 63.4%
 95 75 52
Resistance ≥1CLSI subclass* 37.7% 37.0% 36.6%
 57 44 30
Resistance ≥2 CLSI subclasses* 17.9% 22.7% 22.0%
 27 27 18
Resistance ≥3 CLSI subclasses* 9.9% 14.3% 15.9%
 15 17 13
Resistance ≥4 CLSI subclasses* 5.3% 9.2% 8.5%
 8 11 7
Resistance ≥5 CLSI subclasses* 3.3% 7.6% 1.2%
 5 9 1
At least ACSSuT† 1.3% 0.8% 0.0%
 2 1 0
At least ACSuTm‡ 1.3% 0.8% 1.2%
 2 1 1
At least ACSSuTAuCf§ 0.0% 0.0% 0.0%
 0 0 0
At least AAuC¶ 0.0% 0.0% 0.0%
 0 0 0
At least A3C** 0.0% 0.0% 0.0%
 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0%
 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0%
 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶AAuC: resistance to ampicillin, amoxicillin-clavulanic acid, ceftiofur  
**A3C: resistance to amikacin, ampicillin, amoxicillin-clavulanic acid




Among isolates of commensal E. coli ceftiofur resistance has increased from 0.0% in 2004 to 0.8% in 2005 and 
decreased to 0.0% in 2006.  Ciprofloxacin resistance decreased from 7.6% in 2005 to 4.9% in 2006.  A decrease 
in detected resistance was observed for five drugs; Amoxicillin-clavulanic acid (4.2% to 3.7%), ciprofloxacin (7.6% 
to 4.9%), streptomycin (14.3%–7.3%), sulfamethoxazole/sulfisoxazole (18.4% to 17.1%) and tetracycline (19.3 to 
14.6%). 
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